[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 107
1. Ward BK, Seethala RR, Barnes EL, Lai SY: Basal cell adenocarcinoma of a hard palate minor salivary gland: case report and review of the literature. Head Neck Oncol; 2009 Dec 23;1:41
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma of a hard palate minor salivary gland: case report and review of the literature.
  • OBJECTIVE: Basal cell adenocarcinoma of a minor salivary gland is extremely rare.
  • The goal of this report is to increase awareness of this rare disease and to review and discuss the differential diagnosis and important considerations in treatment.
  • METHODS: Case report of a basal cell adenocarcinoma of a hard palate minor salivary gland and review of the literature of basal cell adenocarcinoma.
  • RESULTS: Basal cell adenocarcinomas are slow-growing tumours that most commonly involve the parotid gland and very rarely involve minor salivary glands.
  • Histological diagnosis is important to distinguish this tumour from adenoid cystic carcinoma given the significant difference in disease prognosis.
  • CONCLUSIONS: Diagnosis of these tumours must be made histologically.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol. 1978 Feb;104(2):111-6 [629699.001]
  • [Cites] J Oral Pathol. 1985 Jul;14(6):500-9 [2991488.001]
  • [Cites] Arch Pathol Lab Med. 1988 Feb;112(2):209-11 [2827601.001]
  • [Cites] J Laryngol Otol. 1989 Aug;103(8):756-9 [2769045.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1990 Apr;69(4):461-9 [2326038.001]
  • [Cites] Cancer. 1996 Dec 15;78(12):2471-7 [8952553.001]
  • [Cites] Oral Oncol. 2008 Apr;44(4):407-17 [17825603.001]
  • [Cites] HNO. 1998 Sep;46(9):821-5 [9816537.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Jul;34(5):528-32 [16053873.001]
  • [Cites] Int J Oral Maxillofac Surg. 2006 Feb;35(2):150-4 [16181771.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2006 Mar;11(2):E206-9 [16505803.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jan;103(1):77-84 [17178498.001]
  • [Cites] J Oral Pathol Med. 2007 Apr;36(4):207-14 [17391298.001]
  • [Cites] Acta Otolaryngol. 1998 Jul;118(4):588-93 [9726688.001]
  • (PMID = 20030819.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / K08 DE018061
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2806868
  • [General-notes] NLM/ Original DateCompleted: 20100629
  •  go-up   go-down


2. Habermann CR, Arndt C, Graessner J, Diestel L, Petersen KU, Reitmeier F, Ussmueller JO, Adam G, Jaehne M: Diffusion-weighted echo-planar MR imaging of primary parotid gland tumors: is a prediction of different histologic subtypes possible? AJNR Am J Neuroradiol; 2009 Mar;30(3):591-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologic diagnosis was obtained in every patient.
  • Mucoepidermoid carcinomas, acinic cell carcinomas, and basal cell adenocarcinomas were not differentiable from Warthin tumors (P = .094, .396, and .604, respectively).
  • Therefore, further studies combining DWI, morphologic criteria, and probably other MR imaging techniques seem warranted.
  • [MeSH-minor] Adenolymphoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / pathology. Carcinoma, Mucoepidermoid / pathology. Diagnosis, Differential. Female. Humans. Lipoma / pathology. Male. Middle Aged. Prospective Studies. Salivary Gland Neoplasms / pathology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131405.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Jingu K, Hasegawa A, Mizo JE, Bessho H, Morikawa T, Tsuji H, Tsujii H, Kamada T: Carbon ion radiotherapy for basal cell adenocarcinoma of the head and neck: preliminary report of six cases and review of the literature. Radiat Oncol; 2010;5:89
Hazardous Substances Data Bank. CARBON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbon ion radiotherapy for basal cell adenocarcinoma of the head and neck: preliminary report of six cases and review of the literature.
  • BACKGROUND: Basal cell adenocarcinoma accounts for approximately 1.6% of all salivary gland neoplasms.
  • METHODS: Case records of 6 patients with diagnosis of basal cell adenocarcinoma of the head and neck, who were treated by carbon ion radiotherapy with 64.0 GyE/16 fractions in our institution, were retrospectively reviewed.
  • CONCLUSIONS: Carbon ion radiotherapy should be considered as an appropriate curative approach for treatment of basal cell adenocarcinoma in certain cases, particularly in cases of unresectable disease and postoperative gross residual or recurrent disease.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Carbon / therapeutic use. Head and Neck Neoplasms / radiotherapy. Heavy Ions / therapeutic use

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):737-43 [11020570.001]
  • [Cites] Histopathology. 2003 Jun;42(6):610-4 [12786899.001]
  • [Cites] Arch Otolaryngol. 1978 Feb;104(2):111-6 [629699.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1990 Apr;69(4):461-9 [2326038.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Am J Clin Oncol. 1992 Oct;15(5):441-5 [1326226.001]
  • [Cites] Cancer. 1996 Dec 15;78(12):2471-7 [8952553.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):439-47 [9452259.001]
  • [Cites] HNO. 1998 Sep;46(9):821-5 [9816537.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):201-10 [10219815.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):71-82 [15915466.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):396-401 [16182466.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2006 Mar;11(2):E206-9 [16505803.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jan;103(1):77-84 [17178498.001]
  • (PMID = 20920325.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 7440-44-0 / Carbon
  • [Other-IDs] NLM/ PMC2958970
  •  go-up   go-down


Advertisement
4. Sanchis García JM, Dualde Beltrán D, Ramírez Sabio JB, Vera González A, Palmero da Cruz J: [Well-differentiated basal cell adenocarcinoma of the lacrimal sac: a case report]. Radiologia; 2007 May-Jun;49(3):201-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Well-differentiated basal cell adenocarcinoma of the lacrimal sac: a case report].
  • [Transliterated title] Adenocarcinoma de células basales del saco lacrimal bien diferenciado. A propósito de un caso.
  • Basal cell adenocarcinoma is a rare tumor first considered to be a separate entity by the WHO in 1991.
  • We present a case of adenocarcinoma of the lacrimal sac diagnosed at histological study.
  • We discuss the differential diagnosis and treatment for this tumor.
  • [MeSH-major] Adenocarcinoma / diagnosis. Lacrimal Apparatus

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17524341.001).
  • [ISSN] 0033-8338
  • [Journal-full-title] Radiología
  • [ISO-abbreviation] Radiologia
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


5. Gupta G, Singh R, Shanmugasamy K, Kotasthane DS, Kotasthane VD: Basal cell adenocarcinoma in the tongue: an unusual presentation. Clin Med Insights Oncol; 2010 Nov 21;4:127-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma in the tongue: an unusual presentation.
  • We present a case of basal cell adenocarcinoma (BCAC) in the tongue in a 65-year old male.
  • The clinicopathological features and the cellular immunophenotype addressed the diagnosis towards BCAC of the tongue.
  • The goal of this report is to increase awareness of this rare disease and to review and discuss the differential diagnosis and important considerations in treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21151583.001).
  • [ISSN] 1179-5549
  • [Journal-full-title] Clinical Medicine Insights. Oncology
  • [ISO-abbreviation] Clin Med Insights Oncol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2999957
  • [Keywords] NOTNLM ; basal cell adenocarcinoma / minor salivary gland / tongue
  •  go-up   go-down


6. Markkanen-Leppänen M, Mäkitie AA, Passador-Santos F, Leivo I, Hagström J: Bilateral Basal cell adenocarcinoma of the parotid gland: in a recipient of kidney transplant. Clin Med Insights Pathol; 2010 Feb 18;3:1-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral Basal cell adenocarcinoma of the parotid gland: in a recipient of kidney transplant.
  • We report a rare case of bilateral basal cell adenocarcinoma (BcAC) of the parotid gland in a male patient 30 years after kidney transplantation and continuous administration of immunosuppressive therapy.
  • The most important differential diagnosis is basal cell adenoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21151548.001).
  • [ISSN] 1179-5557
  • [Journal-full-title] Clinical medicine insights. Pathology
  • [ISO-abbreviation] Clin Med Insights Pathol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2999998
  • [Keywords] NOTNLM ; basal cell adenocarcinoma / immunohistochemistry / post transplantation malignancy / salivary gland cancer
  •  go-up   go-down


7. González-García R, Nam-Cha SH, Muñoz-Guerra MF, Gamallo-Amat C: Basal cell adenoma of the parotid gland. Case report and review of the literature. Med Oral Patol Oral Cir Bucal; 2006 Mar;11(2):E206-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenoma of the parotid gland. Case report and review of the literature.
  • Basal cell adenoma of the salivary glands is an uncommon type of monomorphous adenoma.
  • Histologically, isomorphic cells in nests and interlaced trabecules with a prominent basal membrane are observed.
  • Due to prognostic implications, differential diagnosis with basal cell adenocarcinoma, adenoid cystic carcinoma and basaloid squamous cell carcinoma is mandatory.
  • We describe a case of basal cell adenoma of the parotid gland.
  • We also review the literature and discuss the diagnosis and management of this rare entity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16505803.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 21
  •  go-up   go-down


8. Yamagata K, Oka K, Yoshida H, Yanagawa T, Onizawa K, Yusa H, Ishikawa A, Okada N: Basal cell adenocarcinoma arising from the minor salivary gland in the soft palate: a case report. Pathol Res Pract; 2006;202(6):475-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma arising from the minor salivary gland in the soft palate: a case report.
  • Basal cell adenocarcinomas (BCACs) of the oral minor salivary gland are very rare neoplasms.
  • [MeSH-major] Adenocarcinoma / pathology. Palate, Soft / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16487667.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


9. Farrell T, Chang YL: Basal cell adenocarcinoma of minor salivary glands. Arch Pathol Lab Med; 2007 Oct;131(10):1602-4
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma of minor salivary glands.
  • Basal cell adenocarcinoma of minor salivary glands is a relatively rare slow-growing tumor with an infiltrating growth pattern.
  • The infiltrating growth pattern and likelihood of vascular and perineural involvement distinguishes basal cell adenocarcinoma from basal cell adenoma.
  • Basal cell adenocarcinomas show strong immunoreactivity to cytokeratin 7 and variable myoepithelial staining with S100.
  • It is necessary to differentiate basal cell adenocarcinoma from other basaloid cell tumors of the minor salivary glands because of the prognosis and potential differences in treatment, particularly adenoid cystic adenocarcinoma and basaloid squamous carcinoma.
  • Surgical excision with a wide margin to ensure complete removal has been suggested as the primary treatment for basal cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Salivary Gland Neoplasms / diagnosis. Salivary Glands, Minor / pathology
  • [MeSH-minor] Adenoma / diagnosis. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Squamous Cell / diagnosis. Combined Modality Therapy. Diagnosis, Differential. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922602.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Andreadis D, Epivatianos A, Poulopoulos A, Nomikos A, Papazoglou G, Antoniades D, Barbatis C: Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours. Oral Oncol; 2006 Jan;42(1):57-65
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • C-KIT expression was observed in cases of adenoid cystic, acinic cell polymorphous low grade, epithelial-myoepithelial, carcinosarcoma and basal cell adenocarcinomas, as in luminal cells of pleomorphic adenomas, in serous acinar and only in intercalated and a small number of striated ductal cells of inflammatory salivary gland tissue, whereas normal salivary lobules were generally negative except a weak positivity of intercalated cells.
  • Contrary to other reports, this study suggests that, C-KIT protein does not appear to be an exclusively specific marker for benign or malignant salivary gland neoplasms, but may be useful in differential diagnosis of adenoid cystic carcinoma from polymorphous low grade adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140564.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


11. Salem A, Phillips JS, Joseph JA, O'Donovan DG, Jani P: Basal cell adenocarcinoma of the ethmoid sinuses. J Laryngol Otol; 2007 Sep;121(9):889-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma of the ethmoid sinuses.
  • Basal cell adenocarcinoma is a rare and relatively recently characterised malignant salivary gland tumour.
  • Basal cell adenocarcinoma has only been described once before in the ethmoid sinus.
  • We report a case of basal cell adenocarcinoma in the ethmoid sinus, extending into the right orbit and anterior cranial fossa.
  • We describe the clinical aspects of the patient's management and detail the histopathological features of this very rare diagnosis.
  • [MeSH-major] Adenocarcinoma. Ethmoid Sinus. Paranasal Sinus Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17295935.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Hirai H, Harada H, Okada N, Omura K: A case of basal cell adenocarcinoma of the upper gingiva. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Apr;107(4):542-6
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of basal cell adenocarcinoma of the upper gingiva.
  • Basal cell adenocarcinoma arising from the minor salivary gland is extremely rare.
  • We report a 76-year-old Japanese man with basal cell adenocarcinoma originating in the upper gingiva.
  • [MeSH-major] Adenocarcinoma / surgery. Gingival Neoplasms / surgery. Maxillary Neoplasms / surgery. Oral Surgical Procedures. Reconstructive Surgical Procedures / methods. Salivary Gland Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19157926.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Zheng J, Chen Y, Zhang J: [Basal cell adenocarcinoma of nasal septum: a case report and review of literatures]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Mar;23(5):209-10
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basal cell adenocarcinoma of nasal septum: a case report and review of literatures].
  • OBJECTIVE: To summarize clinical features, diagnosis, differential diagnosis, treatment and prognosis of basal cell adenocarcinoma.
  • METHOD: A retrospective study were subjected to one case with basal cell adenocarcinoma of the nasal septum, and the related literature were reviewed.
  • RESULT: Basal cell adenocarcinoma often occurred in the salivary glands and minor salivary glands of salivary palate and other parts.
  • CONCLUSION: Basal cell adenocarcinoma is rare seen in the salivary gland tumors.
  • [MeSH-major] Adenocarcinoma. Nasal Septum / pathology. Nose Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522187.001).
  • [ISSN] 1001-1781
  • [Journal-full-title] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
  • [ISO-abbreviation] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  •  go-up   go-down


14. Hu J, Zhang Z, Zheng J, Ye W, Tian Z, Zhu H: Unilateral parotid gland involvement with synchronous multiple basal cell adenocarcinomas: case report and review of the literature. J Oral Maxillofac Surg; 2010 Oct;68(10):2579-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unilateral parotid gland involvement with synchronous multiple basal cell adenocarcinomas: case report and review of the literature.
  • [MeSH-major] Adenocarcinoma / pathology. Neoplasms, Multiple Primary / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20096979.001).
  • [ISSN] 1531-5053
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


15. Manor E, Sion-Vardy N, Bodner L: Cytogenetic and fluorescence in situ hybridization analysis of a basal cell adenocarcinoma of the mandible. Cancer Genet Cytogenet; 2006 Apr 15;166(2):186-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic and fluorescence in situ hybridization analysis of a basal cell adenocarcinoma of the mandible.
  • Basal cell adenocarcinoma (BCAC) of the salivary glands is rare.
  • [MeSH-major] Adenocarcinoma / genetics. Mandibular Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16631478.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Parashar P, Baron E, Papadimitriou JC, Ord RA, Nikitakis NG: Basal cell adenocarcinoma of the oral minor salivary glands: review of the literature and presentation of two cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Jan;103(1):77-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma of the oral minor salivary glands: review of the literature and presentation of two cases.
  • Basal cell adenocarcinoma (BCA) is an unusual salivary gland malignancy that very rarely affects the minor glands.
  • [MeSH-major] Adenocarcinoma / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17178498.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


17. Petersen SK, Bjørndal K, Krogdahl A, Godballe C: [Basal cell adenocarcinoma of the sublingual gland]. Ugeskr Laeger; 2010 Feb 15;172(7):551-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basal cell adenocarcinoma of the sublingual gland].
  • [MeSH-major] Adenocarcinoma / pathology. Sublingual Gland Neoplasms / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Edema / diagnosis. Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20156409.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


18. Chung SW, Kwon SY, Jung KY, Woo JS: Synchronous double primary cancers of the unilateral parotid gland. Acta Otolaryngol; 2007 Feb;127(2):209-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we report a 39-year-old woman who exhibited basal cell adenocarcinoma and mucoepidermoid carcinoma simultaneously in the left parotid gland.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Mucoepidermoid / pathology. Neoplasms, Multiple Primary / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17364354.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


19. Kazakov DV, Benkova K, Michal M, Vanecek T, Kacerovska D, Skalova A: Skin type spiradenoma of the parotid gland with malignant transformation: report of a case with analysis of the CYLD gene. Hum Pathol; 2009 Oct;40(10):1499-503

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A distinctive variant of basal cell adenoma called membranous basal cell adenoma is well recognized in salivary glands.
  • In addition, the lesion had a malignant component identical to basal cell adenocarcinoma.
  • [MeSH-minor] Aged. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. DNA Mutational Analysis. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19454360.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CYLD protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


20. Kawahara A, Harada H, Akiba J, Yokoyama T, Kage M: Fine-needle aspiration cytology of basal cell adenoma of the parotid gland: characteristic cytological features and diagnostic pitfalls. Diagn Cytopathol; 2007 Feb;35(2):85-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration cytology of basal cell adenoma of the parotid gland: characteristic cytological features and diagnostic pitfalls.
  • We retrospectively studied the cytological features of aspiration cytology in 12 cases of basal cell adenoma (BCA) and 5 cases mistakenly diagnosed as BCA.
  • The characteristic cytological features of solid type BCA were three-dimensional clusters in 71%, sharp-angle small clusters in 86%, basement membrane- like material in 71%, and cell crush in 86%.
  • In contrast, 3 of the 5 cystic type BCA cases showed inadequate cellular components or no basaloid tumor cells, and the cytological diagnosis of BCA could not be determined.
  • In the 5 cases misdiagnosed as BCA, there were 2 cases of pleomorphic adenoma, 2 cases of benign lymphoepithelial cyst, and 1 case of basal cell adenocarcinoma.
  • Accurate differential cytological diagnosis of BCA is relatively easy to determine the solid type BCA, but is more difficult for cystic type BCA.
  • [MeSH-major] Adenoma / diagnosis. Parotid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biopsy, Fine-Needle. Diagnosis, Differential. Diagnostic Errors. Female. Humans. Male. Middle Aged. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17230571.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Seethala RR, Pasha TL, Raghunath PN, Livolsi VA, Zhang PJ: The selective expression of CD43 in adenoid cystic carcinoma. Appl Immunohistochem Mol Morphol; 2008 Mar;16(2):165-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD43 immunoreactivity with 2 different antibodies was detected mainly in ACC but also 1 membranous type basal cell adenocarcinoma and 1 colonic adenocarcinoma.

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18227725.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD43; 0 / RNA, Messenger; 0 / UN1 sialoglycoprotein, human
  •  go-up   go-down


22. Daneshbod Y, Daneshbod K, Khademi B: Diagnostic difficulties in the interpretation of fine needle aspirate samples in salivary lesions: diagnostic pitfalls revisited. Acta Cytol; 2009 Jan-Feb;53(1):53-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These records and slides were reviewed to identify cytologic characteristics that contributed to false diagnosis.
  • RESULTS: Of a total of 1,040 salivary FNA samples, 376 cases had a final histologic diagnosis with interpretations of benign or malignant.
  • The most common false negative cases were acinic cell carcinoma, epithelial myoepithelial carcinoma, adenoid cystic carcinoma and basal cell adenocarcinoma.
  • Benign cases with false positive diagnosis were Warthin tumor and pleomorphic adenoma.
  • CONCLUSION: Knowledge of cytologic overlaps and pitfalls on salivary gland FNA, as well as clinical and radiologic features, may help clinicians arrive at the appropriate diagnosis and reduce false interpretations.
  • [MeSH-major] Salivary Gland Neoplasms / diagnosis. Salivary Glands / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Child. Child, Preschool. Diagnosis, Differential. False Negative Reactions. False Positive Reactions. Female. Humans. Infant. Male. Middle Aged. Retrospective Studies. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19248555.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Farah-Klibi F, Ferchiou M, Kourda J, El Amine O, Ferjaoui M, Ben Jilani S, Zermani R: [Parotid basal cell adenoma of membranous type]. Tunis Med; 2009 Feb;87(2):149-51
MedlinePlus Health Information. consumer health - Sarcoidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Parotid basal cell adenoma of membranous type].
  • [Transliterated title] Adenome a cellules basales de type membraneux de la parotide.
  • INTRODUCTION: Basal cell adenoma (BCA) is a rare benign neoplasm characterized by the basaloid appearance of the tumour cells and the lack of myxo-chondroid stromal component present in pleomorphic adenoma.
  • AIM: We report a case of basal cell adenoma of membranous type, highly suspected of malignancy because of the presence of mediastinal lymph nodes and pulmonary nodules which finally were related to an associated sarcoidosis.
  • So the diagnosis of metastatic malignant salivary gland tumor was suspected.
  • Finally, the histological examination concluded to a basal cell adenoma of membranous type with sarcoidosis granulomas in the parotid and in the lymph nodes.
  • When the malignancy is suspected, like in our case, this tumor must be differentiated from the basal cell adenocarcinoma using histological criteria.
  • [MeSH-major] Adenoma / diagnosis. Parotid Neoplasms / diagnosis. Sarcoidosis / diagnosis
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Female. Humans. Lymphatic Metastasis. Mediastinum / radiography. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522450.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


24. Campos MS, Modolo F, de Oliveira JS, Pinto-Júnior DS, de Sousa SC: Atypical presentation of oral basaloid squamous cell carcinoma. J Contemp Dent Pract; 2009;10(2):98-104
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical presentation of oral basaloid squamous cell carcinoma.
  • AIM: The purpose of this report is to present the clinical and histological features of a basaloid squamous cell carcinoma (BSCC) occurring in the retromolar trigone of a 59-year-old man and to relate its immunohistochemical characteristics.
  • BACKGROUND: BSCC is an aggressive distinct variant of squamous cell carcinoma (SCC) requiring recognition as a separate entity from SCC due to its peculiar behavior.
  • SUMMARY: Since this tumor can mimic other neoplasms such as adenoid cystic carcinoma, neuroendocrine carcinoma, and basal cell adenocarcinoma, histological features are essential to differentiate between them.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Transitional Cell / diagnosis. Mouth Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Cell Nucleus / ultrastructure. Diagnosis, Differential. Follow-Up Studies. Humans. Immunohistochemistry. Keratins / analysis. Ki-67 Antigen / analysis. Laminin / analysis. Male. Middle Aged. Mitosis. Necrosis. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19279978.001).
  • [ISSN] 1526-3711
  • [Journal-full-title] The journal of contemporary dental practice
  • [ISO-abbreviation] J Contemp Dent Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Laminin; 0 / Tumor Suppressor Protein p53; 68238-35-7 / Keratins
  •  go-up   go-down


25. Chetty R, Serra S, Hsieh E: Basaloid squamous carcinoma of the anal canal with an adenoid cystic pattern: histologic and immunohistochemical reappraisal of an unusual variant. Am J Surg Pathol; 2005 Dec;29(12):1668-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histologic differential diagnosis is true salivary gland-type adenoid cystic carcinoma and basal cell adenocarcinoma.
  • Immunohistochemistry and awareness of this unusual pattern of BSC will facilitate the correct diagnosis being reached.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Basal Cell / pathology. Carcinoma, Basosquamous / pathology
  • [MeSH-minor] Antibiotics, Antineoplastic / therapeutic use. Antigens, CD20 / metabolism. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Cisplatin / therapeutic use. DNA-Binding Proteins. Female. Fluorouracil / therapeutic use. Follow-Up Studies. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Keratins / metabolism. Middle Aged. Mitomycin / therapeutic use. Phosphoproteins / metabolism. Radiotherapy. Time Factors. Trans-Activators / metabolism. Transcription Factors. Treatment Outcome. Tumor Burden. Tumor Suppressor Proteins

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16327441.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antigens, CD20; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 50SG953SK6 / Mitomycin; 68238-35-7 / Keratins; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


26. Akrish S, Peled M, Ben-Izhak O, Nagler RM: Malignant salivary gland tumors and cyclo-oxygenase-2: a histopathological and immunohistochemical analysis with implications on histogenesis. Oral Oncol; 2009 Dec;45(12):1044-50
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Strong cox-2 overexpression was noted in all MST of proposed excretory duct origin: salivary duct carcinoma (100%), mucoepidermoid carcinoma (MEC) (92%), and adenocarcinoma nos (AdC nos) (83%).
  • Primary squamous cell carcinoma (PSCC) was the exception.
  • Negative expression was noted in all tumors of proposed intercalated duct origin (adenoid cystic carcinoma, basal cell adenocarcinoma and acinic cell carcinoma) with the exception of one case of polymorphous low grade adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19729335.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


27. Vasudev P, Boutross-Tadross O, Radhi J: Basaloid squamous cell carcinoma: two case reports. Cases J; 2009;2:9351
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous cell carcinoma: two case reports.
  • Basaloid squamous cell carcinoma (BSCC) is a rare and aggressive variant of squamous cell carcinoma (SCC) that occurs preferentially in the upper aerodigestive tract.
  • BSCC of the head and neck should be distinguished from adenoid cystic carcinoma, small cell neuroendocrine carcinoma, basal cell adenocarcinoma, adenosquamous carcinoma, squamous cell carcinoma, spindle cell squamous carcinoma, mucoepidermoid carcinoma, and adenoid cystic carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2008 Jan;44(2):244-50 [18096379.001]
  • [Cites] Auris Nasus Larynx. 2007 Mar;34(1):119-23 [17141998.001]
  • [Cites] Histopathology. 2000 Sep;37(3):218-23 [10971697.001]
  • [Cites] Hum Pathol. 1986 Nov;17(11):1158-66 [3770734.001]
  • [Cites] Ophthalmology. 1993 Nov;100(11):1720-2 [8233401.001]
  • (PMID = 20062602.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2804002
  •  go-up   go-down


28. Hara H, Oyama T, Saku T: Fine needle aspiration cytology of basal cell adenoma of the salivary gland. Acta Cytol; 2007 Sep-Oct;51(5):685-91
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of basal cell adenoma of the salivary gland.
  • OBJECTIVE: To formulate cytologic features for differential diagnosis of basal cell adenoma (BCA).
  • STUDY DESIGN: The usefulness of 5 items for a cytologically definitive diagnosis of BCA was examined.
  • The 5 items in 8 BCA and 22 non-BCA cases (adenoid cystic carcinoma [ADCC], basal cell adenocarcinoma, myoepithelioma, pleomorphic adenoma and polymorphous low-grade adenocarcinoma) that displayed mimicking cytology were examined cytologically.
  • RESULTS: The useful items were < 5.1 microm in mean of epithelial nuclear short diameter; mild atypia on definitive diagnosis; stromal cell cluster combining smooth margin surrounding the epithelial cell cluster or containing the epithelial cell cluster; epithelial clusters surrounded by or adhered to a thick, hyalinized smooth margin without stromal cluster; and closely fastened, tight clusters with denser cytoplasm than ADCC, but an indistinct border, with oval nuclei and no hyaline cells.
  • [MeSH-minor] Adenocarcinoma / pathology. Biopsy, Fine-Needle. Carcinoma, Adenoid Cystic / pathology. Cell Nucleus / pathology. Diagnosis, Differential. Epithelium / pathology. Epithelium / ultrastructure. Humans. Immunohistochemistry. Myoepithelioma / pathology. Organelle Size. Stromal Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17910337.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


29. Toida M, Shimokawa K, Makita H, Kato K, Kobayashi A, Kusunoki Y, Hatakeyama D, Fujitsuka H, Yamashita T, Shibata T: Intraoral minor salivary gland tumors: a clinicopathological study of 82 cases. Int J Oral Maxillofac Surg; 2005 Jul;34(5):528-32
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologically, the tumors were classified as pleomorphic adenoma (n = 54), papillary cystadenoma (n = 1), adenoid cystic carcinoma (n = 10), mucoepidermoid carcinoma (n = 8), acinic cell carcinoma (n = 3), adenocarcinoma (n = 2), basal cell adenocarcinoma (n = 1), papillary cystadenocarcinoma (n = 1), and carcinoma in pleomorphic adenoma (n = 2).
  • From the results of the present study and review of the literature, it is suggested that the minor salivary gland tumors in Japan may be characterized by a higher incidence of benign tumors, especially of pleomorphic adenoma; a more marked tendency for female predominance; a higher incidence of palatal involvement; and a rarer occurrence of polymorphous low grade adenocarcinoma, in comparison with those reported in the literature from outside of Japan.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenoma, Pleomorphic / epidemiology. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / epidemiology. Carcinoma, Mucoepidermoid / epidemiology. Cheek / pathology. Child. Female. Humans. Japan / epidemiology. Lip / pathology. Male. Middle Aged. Palate / pathology. Retrospective Studies. Sex Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16053873.001).
  • [ISSN] 0901-5027
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


30. Paschoud S, Bongiovanni M, Pache JC, Citi S: Claudin-1 and claudin-5 expression patterns differentiate lung squamous cell carcinomas from adenocarcinomas. Mod Pathol; 2007 Sep;20(9):947-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudin-1 and claudin-5 expression patterns differentiate lung squamous cell carcinomas from adenocarcinomas.
  • We investigated the expression of tight junction proteins in human lung squamous cell carcinomas and adenocarcinomas by immunohistochemistry and quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR).
  • We found a statistically significant correlation between diagnosis and positivity of tumors with either claudin (CLDN)-1 or CLDN-5.
  • Squamous cell carcinomas and basal cells of bronchial epithelium were positive for CLDN-1 and negative for CLDN-5, whereas adenocarcinomas, normal cylindrical cells and pneumocytes were positive for CLDN-5 and negative for CLDN-1, suggesting different pathways in tumor development and progression.
  • CLDN-4 and ZO-1 staining were detected in both types of tumors, whereas cingulin (CGN) was not detected in squamous cell carcinomas.
  • In squamous cell carcinomas, we observed statistically significant decreases in the mRNA levels of JAM-1, occludin, CLDN-3, CLDN-4, CLDN-7, CGN, ZO-2 and ZO-3, and an increase in CLDN-1 mRNA.
  • In adenocarcinomas, when transcript levels were compared with bronchial cells, we observed statistically significant decreases in the mRNA levels of CLDN-1, CLDN-3, CLDN-4, CLDN-7, ZO-2 and ZO-3.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. Lung Neoplasms / diagnosis. Membrane Proteins / analysis. Tight Junctions / chemistry
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Claudin-1. Claudin-4. Claudin-5. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Microfilament Proteins / analysis. Middle Aged. Neoplasm Staging. Phosphoproteins / analysis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Zonula Occludens-1 Protein

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17585317.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CGN protein, human; 0 / CLDN1 protein, human; 0 / CLDN4 protein, human; 0 / CLDN5 protein, human; 0 / Claudin-1; 0 / Claudin-4; 0 / Claudin-5; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / Phosphoproteins; 0 / RNA, Messenger; 0 / TJP1 protein, human; 0 / Zonula Occludens-1 Protein
  •  go-up   go-down


31. Breuninger S, Reidenbach S, Sauer CG, Ströbel P, Pfitzenmaier J, Trojan L, Hofmann I: Desmosomal plakophilins in the prostate and prostatic adenocarcinomas: implications for diagnosis and tumor progression. Am J Pathol; 2010 May;176(5):2509-19
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmosomal plakophilins in the prostate and prostatic adenocarcinomas: implications for diagnosis and tumor progression.
  • The plakophilins, members of the armadillo-repeat family, consist of three different proteins (PKP1-3) that are specifically recruited to desmosomal plaques in a highly cell type-specific manner.
  • Using immunofluorescence, immunoelectron microscopy, and immunoblot, we found that all three plakophilins occurred in luminal and basal cells of the pseudostratified prostate epithelium.
  • The analysis of 135 cases of prostatic adenocarcinomas grouped into tumors with low (Gleason score < or = 6), intermediate (Gleason score 7), and high Gleason score (8 < or = Gleason score < or = 10) showed that the expression of PKP1 was reduced or lost in adenocarcinomas with high Gleason scores.
  • The expression of PKP2 was unchanged in all prostatic adenocarcinomas analyzed.
  • In DU 145 cell lines with either overexpression or knockdown of PKP3, both imbalances resulted in fewer desmosomal cell contacts.
  • [MeSH-major] Adenocarcinoma / metabolism. Desmosomes / metabolism. Gene Expression Regulation, Neoplastic. Plakophilins / metabolism. Prostate / metabolism. Prostatic Neoplasms / metabolism
  • [MeSH-minor] Aged. Cell Adhesion. Cell Proliferation. Disease Progression. Humans. Male. Middle Aged. Phenotype

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7795-800 [11416169.001]
  • [Cites] J Cell Biochem. 2005 Oct 1;96(2):390-403 [15988759.001]
  • [Cites] Mol Biol Cell. 2002 May;13(5):1665-76 [12006661.001]
  • [Cites] Exp Cell Res. 2003 Apr 15;285(1):114-30 [12681292.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):565-72 [12827610.001]
  • [Cites] Crit Rev Oncol Hematol. 2003 Jun 27;46 Suppl:S3-10 [12850522.001]
  • [Cites] Histopathology. 2003 Sep;43(3):209-19 [12940773.001]
  • [Cites] J Cutan Pathol. 2003 Nov;30(10):621-30 [14744087.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Apr;5(4):271-81 [15071552.001]
  • [Cites] J Cell Biol. 2004 Oct 11;167(1):149-60 [15479741.001]
  • [Cites] J Cell Biol. 1988 May;106(5):1679-91 [3131348.001]
  • [Cites] Differentiation. 1994 Dec;58(2):113-31 [7890138.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1995 Jan;31(1):14-24 [7535634.001]
  • [Cites] J Cell Biol. 1996 Nov;135(4):1009-25 [8922383.001]
  • [Cites] J Invest Dermatol. 1997 Feb;108(2):139-46 [9008225.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1784-7 [9065401.001]
  • [Cites] Cell Tissue Res. 1997 Dec;290(3):481-99 [9369526.001]
  • [Cites] Br J Dermatol. 1999 Feb;140(2):297-307 [10233227.001]
  • [Cites] Differentiation. 1999 Jun;64(5):277-90 [10374264.001]
  • [Cites] Differentiation. 1999 Jun;64(5):291-306 [10374265.001]
  • [Cites] J Cell Sci. 1999 Jul;112 ( Pt 14):2265-76 [10381383.001]
  • [Cites] Exp Cell Res. 1999 Aug 1;250(2):452-64 [10413599.001]
  • [Cites] Eur J Cell Biol. 2005 Mar;84(2-3):189-204 [15819400.001]
  • [Cites] Eur J Cell Biol. 2005 Mar;84(2-3):205-14 [15819401.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1228-42 [16096414.001]
  • [Cites] Mol Biol Cell. 2006 Mar;17(3):1388-98 [16407409.001]
  • [Cites] Hum Pathol. 2006 May;37(5):613-22 [16647960.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1773(1):78-88 [17030444.001]
  • [Cites] Histopathology. 2007 Jul;51(1):87-97 [17593084.001]
  • [Cites] Cell Commun Adhes. 2007 Mar-Jun;14(2-3):99-109 [17668353.001]
  • [Cites] Biochim Biophys Acta. 2008 Mar;1778(3):660-9 [17854762.001]
  • [Cites] J Invest Dermatol. 2008 Jun;128(6):1375-85 [18079750.001]
  • [Cites] J Cell Biol. 2008 May 19;181(4):605-13 [18474624.001]
  • [Cites] Int J Cancer. 2008 Nov 15;123(10):2303-14 [18729189.001]
  • [Cites] Histochem Cell Biol. 2008 Nov;130(5):943-56 [18600340.001]
  • [Cites] J Cell Sci. 2009 Jan 1;122(Pt 1):21-4 [19092057.001]
  • [Cites] Cell Tissue Res. 2008 Dec;334(3):381-99 [19005682.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7102-10 [16103059.001]
  • [Cites] Eur J Cell Biol. 2001 Sep;80(9):567-79 [11675932.001]
  • (PMID = 20348237.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / PKP1 protein, human; 0 / PKP3 protein, human; 0 / Plakophilins
  • [Other-IDs] NLM/ PMC2861115
  •  go-up   go-down


32. Gassler N, Herr I, Schneider A, Penzel R, Langbein L, Schirmacher P, Kopitz J: Impaired expression of acyl-CoA synthetase 5 in sporadic colorectal adenocarcinomas. J Pathol; 2005 Nov;207(3):295-300
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impaired expression of acyl-CoA synthetase 5 in sporadic colorectal adenocarcinomas.
  • In the present study, gene expression, protein synthesis, and enzymatic activity of ACS5 in sporadic colorectal adenocarcinomas, adenomas, and established cell lines were analysed using RT-PCR, western blot analysis, immunofluorescence, and an enzymatic assay.
  • Enhanced expression of ACS5 mRNA and protein as well as enzymatic activity was found in adenomas and in 11 (73%; group 1) of 15 colorectal adenocarcinomas investigated, while a decrease of ACS5 was seen in four tumours (27%; group 2).
  • However, basal ACS5 enzymatic activity was increased as a percentage of the total activity of ACSs in both groups, arguing for an absolute (group 1) or relative (group 2) increase in ACS5 enzymatic activity in all adenocarcinomas investigated.
  • These findings are reflected by in vitro analysis of three established colorectal adenocarcinoma cell lines, in which activity of ACS5 occurred.
  • [MeSH-major] Adenocarcinoma / metabolism. Coenzyme A Ligases / metabolism. Colorectal Neoplasms / metabolism
  • [MeSH-minor] Adenoma / enzymology. Adenoma / genetics. Adenoma / metabolism. Aged. Aged, 80 and over. Cell Line, Tumor. Colon / enzymology. Colon / metabolism. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Intestinal Mucosa / metabolism. Male. Middle Aged. Neoplasm Proteins / biosynthesis. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Rectum / enzymology. Rectum / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 16110457.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 6.2.1.- / Coenzyme A Ligases; EC 6.2.1.- / acyl CoA synthetase 5
  •  go-up   go-down


33. Iczkowski KA, Montironi R: Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu. J Clin Pathol; 2006 Dec;59(12):1327-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu.
  • Adenoid cystic/basal cell carcinoma (ACBCC) is a rare neoplasm in the prostate.
  • Ten acinar adenocarcinomas of varying grades were also immunostained as controls.
  • Benign acini expressed HER-2/neu only in the basal layer.
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Basal Cell / metabolism. Mixed Tumor, Malignant / metabolism. Prostatic Neoplasms / metabolism. Receptor, ErbB-2 / metabolism


34. Gubbay O, Guo W, Rae MT, Niven D, Langdon SP, Hillier SG: Inflammation-associated gene expression is altered between normal human ovarian surface epithelial cells and cell lines derived from ovarian adenocarcinomas. Br J Cancer; 2005 May 23;92(10):1927-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammation-associated gene expression is altered between normal human ovarian surface epithelial cells and cell lines derived from ovarian adenocarcinomas.
  • In this study we directly compared levels of IL-1alpha-induced gene expression by analysing the levels of 11beta-hydroxysteroid dehydrogenase (11betaHSD) types 1 (11betaHSD-1) and 2 (11betaHSD-2), cyclooxygenase-2 (COX-2), IL-1 receptor (IL-1R) and glucocorticoid receptor alpha (GRalpha) mRNA between normal HOSE cells and cell lines derived from poorly differentiated (SKOV-3, BG-1, PEO-4) and well-differentiated (PEO-14) ovarian adenocarcinoma.
  • In HOSE cell cultures, and to a lesser extent PEO-14 cells, the basal mRNA levels of COX-2 and 11betaHSD-1 were relatively high and further shown to be induced in response to IL-1alpha (for HOSE cells; >20-fold, P<0.05 and PEO-14 cells; >3fold, P<0.05).
  • However, whereas HOSE cells expressed a low level of 11betaHSD-2 mRNA that was only mildly responsive to IL-1alpha (1.3-fold, P<0.001), all cell lines exhibited a higher basal level of 11betaHSD-2 mRNA that was in some cases further stimulated in PEO-4 cells (five-fold; P<0.05) or suppressed in SKOV-3 cells (two-fold; P<0.01) in response to IL-1alpha.
  • These results indicate that cell lines derived from ovarian cancers have lost the ability to respond normally to inflammatory cytokines such as IL-1alpha.
  • The finding that normal OSE cells, in contrast to cell lines derived from patients with ovarian adenocarcinoma, abundantly express 11betaHSD-1 mRNA but are essentially devoid of 11betaHSD-2 mRNA supports the concept that the pattern of 11betaHSD isoform gene expression is a defining feature of neoplastic cellular transformation, which might have particular relevance to the ovary.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / immunology. Cytokines / biosynthesis. Cytokines / genetics. Gene Expression Regulation. Inflammation. Ovarian Neoplasms / genetics. Ovarian Neoplasms / immunology
  • [MeSH-minor] 11-beta-Hydroxysteroid Dehydrogenases / biosynthesis. Cell Differentiation. Cell Transformation, Neoplastic. Cyclooxygenase 2. Epithelial Cells. Female. Humans. Interleukin-1 / pharmacology. Membrane Proteins. Ovulation. Prostaglandin-Endoperoxide Synthases / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Treat Rev. 1991 Mar;18 Suppl A:77-83 [1904312.001]
  • [Cites] Am J Pathol. 1991 Feb;138(2):455-63 [1992770.001]
  • [Cites] J Cancer Res Clin Oncol. 1991;117(6):587-92 [1744165.001]
  • [Cites] Am J Obstet Gynecol. 1992 Dec;167(6):1864-9 [1471711.001]
  • [Cites] Cancer Immunol Immunother. 1993 Jul;37(1):26-30 [8513450.001]
  • [Cites] J Leukoc Biol. 1993 Oct;54(4):314-21 [8409753.001]
  • [Cites] Biol Reprod. 1994 Feb;50(2):233-8 [8142541.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):707-14 [8151314.001]
  • [Cites] Gynecol Oncol. 1994 Apr;53(1):70-7 [7909787.001]
  • [Cites] Gynecol Oncol. 1994 Nov;55(2):294-303 [7959299.001]
  • [Cites] Hum Reprod. 1994 Oct;9(10):1944-9 [7844231.001]
  • [Cites] Steroids. 1995 Jan;60(1):143-6 [7792800.001]
  • [Cites] Mol Pharmacol. 1995 Jun;47(6):1255-60 [7603468.001]
  • [Cites] Int J Cancer. 1996 Sep 17;67(6):826-30 [8824555.001]
  • [Cites] Eur J Cancer. 1996 Aug;32A(9):1609-11 [8911126.001]
  • [Cites] Int J Cancer. 1996 Nov 27;68(5):583-7 [8938138.001]
  • [Cites] J Biol Chem. 1996 Dec 6;271(49):31496-501 [8940164.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 18;88(24):1810-20 [8961970.001]
  • [Cites] Eur J Biochem. 1996 Dec 15;242(3):544-9 [9022680.001]
  • [Cites] J Biol Chem. 1997 Mar 21;272(12):8083-9 [9065483.001]
  • [Cites] Hiroshima J Med Sci. 1997 Mar;46(1):51-9 [9114567.001]
  • [Cites] J Exp Med. 1997 Jul 21;186(2):189-98 [9221748.001]
  • [Cites] Eur Cytokine Netw. 1997 Jun;8(2):179-87 [9262967.001]
  • [Cites] Anim Reprod Sci. 1997 Jun;47(3):197-204 [9329861.001]
  • [Cites] Br J Obstet Gynaecol. 1997 Dec;104(12):1407-8 [9422021.001]
  • [Cites] J Reprod Immunol. 1998 Aug;39(1-2):21-7 [9786451.001]
  • [Cites] J Biol Chem. 1998 Oct 30;273(44):28670-6 [9786861.001]
  • [Cites] Eur J Cancer. 1998 May;34(6):931-3 [9797710.001]
  • [Cites] FEBS Lett. 1999 Jan 8;442(1):57-60 [9923604.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67 [10469746.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1053-65 [15558012.001]
  • [Cites] Exp Cell Res. 2000 Jan 10;254(1):14-24 [10623461.001]
  • [Cites] J Reprod Fertil. 1999 Nov;117(2):325-9 [10690200.001]
  • [Cites] Hum Reprod Update. 2000 Jan-Feb;6(1):1-15 [10711825.001]
  • [Cites] Gynecol Oncol. 2000 Oct;79(1):67-73 [11006034.001]
  • [Cites] Epidemiology. 2000 Mar;11(2):111-7 [11021606.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]
  • [Cites] Prev Med. 2001 Dec;33(6):682-7 [11716667.001]
  • [Cites] Hum Reprod. 2002 Sep;17(9):2300-6 [12202416.001]
  • [Cites] J Soc Gynecol Investig. 2002 Nov-Dec;9(6):386-90 [12445604.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6A):3421-4 [12530098.001]
  • [Cites] Mol Cell. 2003 Feb;11(2):293-302 [12620219.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Jun;85(2-5):415-21 [12943730.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1501-4 [14504049.001]
  • [Cites] Reproduction. 2003 Oct;126(4):425-41 [14525525.001]
  • [Cites] Curr Opin Immunol. 2003 Dec;15(6):704-8 [14630206.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1205-8 [14652282.001]
  • [Cites] Ginekol Pol. 2003 Sep;74(9):761-6 [14674121.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3550-8 [15150111.001]
  • [Cites] Mol Immunol. 2004 Jul;41(6-7):577-82 [15219996.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):630-5 [15350351.001]
  • [Cites] Am J Physiol. 1999 Nov;277(5 Pt 1):L943-51 [10564179.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Sep;89(9):4538-44 [15356059.001]
  • [Cites] Oncogene. 2004 Oct 7;23(46):7726-33 [15361843.001]
  • [Cites] Lancet. 1971 Jul 17;2(7716):163 [4104488.001]
  • [Cites] Biol Reprod. 1980 Feb;22(1):73-106 [6991013.001]
  • [Cites] Eur J Cell Biol. 1985 May;37:175-90 [3896804.001]
  • [Cites] Cancer Res. 1988 Nov 1;48(21):6166-72 [3167863.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16653-8 [1885595.001]
  • (PMID = 15870720.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-1; 0 / Membrane Proteins; EC 1.1.1.146 / 11-beta-Hydroxysteroid Dehydrogenases; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  • [Other-IDs] NLM/ PMC2361768
  •  go-up   go-down


35. Kong CS, Beck AH, Longacre TA: A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas. Am J Surg Pathol; 2010 Jul;34(7):915-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas.
  • Endometrial and endocervical adenocarcinomas may seem histologically identical and it can be difficult to determine primary site of origin based on morphology alone.
  • The TMA consisted of 214 endometrial carcinomas, 33 endocervical adenocarcinomas, and 36 problematic cases.
  • The endometrial and endocervical carcinomas represented usual endometrioid and mucinous types, and special variants (uterine serous carcinoma, uterine clear cell carcinoma, minimal deviation endocervical adenocarcinoma, cervical small cell carcinoma, adenoid basal cell carcinoma, mesonephric carcinoma).
  • Using a script written in R, the diagnostic accuracy of all possible combinations of markers was evaluated and it was shown that a 3 marker panel including vimentin, ER, or PR, and an HPV marker (p16, ProExC, or HPV ISH) is optimal for determining site of origin for usual endometrial and endocervical adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Cyclin-Dependent Kinase Inhibitor p16 / analysis. DNA, Viral / analysis. Endometrial Neoplasms / diagnosis. Papillomaviridae / genetics. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Papillomavirus Infections / diagnosis. Reproducibility of Results. Tissue Array Analysis. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534993.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NLM NIH HHS / LM / T15 LM007033
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral; 0 / Vimentin
  • [Other-IDs] NLM/ NIHMS775595; NLM/ PMC4847142
  •  go-up   go-down


36. Plaza JA, Ortega PF, Stockman DL, Suster S: Value of p63 and podoplanin (D2-40) immunoreactivity in the distinction between primary cutaneous tumors and adenocarcinomas metastatic to the skin: a clinicopathologic and immunohistochemical study of 79 cases. J Cutan Pathol; 2010 Apr;37(4):403-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of p63 and podoplanin (D2-40) immunoreactivity in the distinction between primary cutaneous tumors and adenocarcinomas metastatic to the skin: a clinicopathologic and immunohistochemical study of 79 cases.
  • Thirty seven primary tumors and 42 cutaneous metastatic adenocarcinomas were evaluated.
  • The 37 primary cutaneous tumors included 14 cases of benign adnexal tumors, 9 malignant skin adnexal neoplasms, and 14 primary squamous and basal cell carcinomas.
  • The 42 metastatic adenocarcinomas all corresponded to metastases from patients with a well-documented history of a primary tumor at another location.
  • We found variable positivity with podoplanin in all primary cutaneous neoplasms including spiradenoma (6/6), hidradenoma (2/4), cylindroma (3/3), desmoplastic trichilemmoma (1/1), poorly differentiated squamous cell carcinoma (4/4), sebaceous carcinoma (1/1), basal cell carcinoma (4/10), trichilemmal carcinoma (2/2), eccrine carcinoma (3/3), microcystic adnexal carcinoma (1/1), adnexal carcinoma NOS (1/1), and porocarcinoma (1/1).
  • The results of our study suggest that the combined expression of p63 and podoplanin are a useful adjunct for the diagnosis of skin tumors in the clinical setting of a questionable metastasis and may be relatively specific for distinguishing primary skin tumors from metastatic carcinomas to the skin.
  • [MeSH-major] Adenocarcinoma / metabolism. Membrane Glycoproteins / metabolism. Membrane Proteins / metabolism. Skin / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20377670.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / PDPN protein, human
  •  go-up   go-down


37. Teulière J, Faraldo MM, Deugnier MA, Shtutman M, Ben-Ze'ev A, Thiery JP, Glukhova MA: Targeted activation of beta-catenin signaling in basal mammary epithelial cells affects mammary development and leads to hyperplasia. Development; 2005 Jan;132(2):267-77
SciCrunch. Marmoset Gene list: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted activation of beta-catenin signaling in basal mammary epithelial cells affects mammary development and leads to hyperplasia.
  • Wnt/beta-catenin signaling pathway is involved in the maintenance of the progenitor cell population in the skin, intestine and other tissues, and its aberrant activation caused by stabilization of beta-catenin contributes to tumorigenesis.
  • In the mammary gland, constitutive activation of Wnt/beta-catenin signaling in luminal secretory cells results in precocious lobuloalveolar differentiation and induces adenocarcinomas, whereas the impact of this signaling pathway on the function of the second major mammary epithelial cell lineage, the basal myoepithelial cells, has not been analyzed.
  • We have used the keratin (K) 5 promoter to target the expression of stabilized N-terminally truncated beta-catenin to the basal cell layer of mouse mammary epithelium.
  • Nulliparous transgenic females developed mammary hyperplasia that comprised undifferentiated basal (K5/14-positive, K8- and alpha-smooth muscle-actin-negative) cells.
  • Multiparous mice, in addition, developed invasive basal-type carcinomas.
  • Thus, activation of beta-catenin signaling in basal mammary epithelial cells affects the entire process of mammary gland development and induces amplification of basal-type cells that lack lineage markers, presumably, a subpopulation of mammary progenitors able to give rise to tumors.
  • [MeSH-minor] Adenocarcinoma / metabolism. Animals. Blotting, Southern. Blotting, Western. Cell Differentiation. Cell Lineage. Cell Proliferation. DNA Primers / chemistry. Epithelium / pathology. Female. Hyperplasia / metabolism. Immunohistochemistry. In Situ Nick-End Labeling. Mice. Mice, Inbred C57BL. Mice, Transgenic. Microscopy, Fluorescence. Phosphoproteins / genetics. Polymerase Chain Reaction. Promoter Regions, Genetic. Protein Structure, Tertiary. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Time Factors. beta Catenin

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15590737.001).
  • [ISSN] 0950-1991
  • [Journal-full-title] Development (Cambridge, England)
  • [ISO-abbreviation] Development
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CTNNB1 protein, mouse; 0 / Cytoskeletal Proteins; 0 / DNA Primers; 0 / Phosphoproteins; 0 / RNA, Messenger; 0 / Trans-Activators; 0 / Trp63 protein, mouse; 0 / beta Catenin
  •  go-up   go-down


38. Hasegawa M, Hagiwara S, Sato T, Jijiwa M, Murakumo Y, Maeda M, Moritani S, Ichihara S, Takahashi M: CD109, a new marker for myoepithelial cells of mammary, salivary, and lacrimal glands and prostate basal cells. Pathol Int; 2007 May;57(5):245-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD109, a new marker for myoepithelial cells of mammary, salivary, and lacrimal glands and prostate basal cells.
  • The CD109 gene encodes a glycosylphosphatidylinositol (GPI)-anchored cell surface protein.
  • Herein it is shown that CD109 is highly expressed in myoepithelial cells of mammary, salivary, and lacrimal glands; and in prostate basal cells.
  • The anti-CD109 antibody generated by the authors was available for formalin-fixed paraffin section, and it strongly stained myoepithelial cells and basal cells but not ductal, acinar, and secretory cells in these glands.
  • CD109 expression was negative in examined breast ductal carcinomas and prostate adenocarcinomas.
  • These findings indicate that CD109 is a useful marker for the diagnosis of invasive breast and prostate carcinomas.
  • [MeSH-minor] Blotting, Western. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cell Line. Cell Line, Tumor. Female. GPI-Linked Proteins. Humans. Immunohistochemistry. Lacrimal Apparatus / chemistry. Lacrimal Apparatus / cytology. Male. Mammary Glands, Human / chemistry. Mammary Glands, Human / cytology. Prostate / chemistry. Prostate / cytology. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. RNA Interference. Salivary Gland Neoplasms / metabolism. Salivary Gland Neoplasms / pathology. Salivary Glands / chemistry. Salivary Glands / cytology. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493171.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers; 0 / CD109 protein, human; 0 / GPI-Linked Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


39. Herawi M, Epstein JI: Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate. Am J Surg Pathol; 2007 Jun;31(6):889-94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
  • Overexpression of alpha-methylacyl coenzyme A racemase (AMACR) in combination with absence of basal cell markers [ie, p63 and high molecular weight cytokeratin (HMWCK)] is typical of classic acinar prostatic adenocarcinoma.
  • We studied the expression and diagnostic utility of p63/HMWCK/AMACR immunohistochemical cocktail staining in ductal adenocarcinoma and cribriform Gleason pattern 4 acinar prostate cancer and compared it to noncribriform Gleason pattern 4 acinar prostate cancer.
  • One to 4 representative formalin-fixed paraffin-embedded archival tissue blocks from 62 radical prostatectomy specimens harboring prostate cancer of ductal (n=51), cribriform Gleason pattern 4 acinar (n=27), and noncribriform Gleason pattern 4 acinar adenocarcinoma (n=48) were included in this study.
  • The percentage of staining intensity and the presence of occasional basal cells positive with p63/HMWCK were recorded in each histologic type of prostatic adenocarcinoma.
  • Seventy-seven percent of ductal prostatic adenocarcinoma, 67% of cribriform acinar prostatic carcinoma, and 81% of noncribriform acinar prostatic carcinoma showed positive staining for AMACR.
  • Basal cells were detectable by p63 and HMWCK in a patchy fashion in 31.4% (16/51) of ductal and 29.6% (8/27) of cribriform acinar carcinomas compared with 2.1% (1/48) of noncribriform acinar carcinomas. In summary:.
  • (3) patchy basal cell staining in noncribriform acinar prostatic carcinoma is rare.
  • In contrast, remnants of basal cells identified by p63/HMWCK were seen in a patchy fashion in a significant minority of both ductal and cribriform acinar prostatic adenocarcinoma, which most likely represents intraductal spread of tumor.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Keratins / metabolism. Membrane Proteins / metabolism. Prostatic Neoplasms / diagnosis. Racemases and Epimerases / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17527076.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 68238-35-7 / Keratins; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


40. Uke M, Rekhi B, Ajit D, Jambhekar NA: The use of p63 as an effective immunomarker in the diagnosis of pulmonary squamous cell carcinomas on de-stained bronchial lavage cytological smears. Cytopathology; 2010 Feb;21(1):56-63
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of p63 as an effective immunomarker in the diagnosis of pulmonary squamous cell carcinomas on de-stained bronchial lavage cytological smears.
  • OBJECTIVES: A diagnosis in pulmonary onco-cytopathology primarily necessitates distinguishing small cell carcinoma (SCLC) from non-small cell carcinoma (NSCLC), which includes squamous cell carcinoma and adenocarcinoma.
  • Lately, p63 antibody has been used for distinguishing squamous cell carcinoma from SCLC and adenocarcinoma.
  • METHODS: A single Papanicolaou-stained conventional smear was de-stained and re-fixed with cold acetone and methanol for immunocytochemical staining with p63 antibody.
  • RESULTS: Out of 100 cases, 21 were cytologically diagnosed as squamous cell carcinoma.
  • Twenty of these showed 2+ or 3+ p63 positivity, whereas one, which was adenocarcinoma on histology, showed 1+ staining.
  • Of seven cases cytologically diagnosed as adenocarcinoma, six showed no p63 staining, whereas one, which was squamous cell carcinoma on histology, showed 1+ staining.
  • The former three were found to be SCLC on histology while the latter was squamous cell carcinoma.
  • The former eight were adenocarcinoma on histology and the latter two were squamous cell carcinoma.
  • The 10 cases that showed 1+ p63 staining were adenocarcinomas (n = 5), squamous cell carcinoma (n = 4) and NSCLC, not otherwise specified (n = 1).
  • Positive staining was seen in normal basal cells, which acted as an internal control.
  • Overall sensitivity of p63 for squamous cell carcinoma was 100% and specificity was 90.4%.
  • CONCLUSIONS: p63 immunostaining on processed cytology smears can be used to help identify squamous cell carcinoma.
  • Its diffuse expression was specific for squamous cell carcinoma while focal staining was also seen in adenocarcinoma.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / pathology. Trans-Activators / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Aged. Aged, 80 and over. Bronchoalveolar Lavage / methods. Bronchoalveolar Lavage Fluid / cytology. Carcinoma, Non-Small-Cell Lung / diagnosis. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Transcription Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19744186.001).
  • [ISSN] 1365-2303
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


41. Sholl LM, Long KB, Hornick JL: Sox2 expression in pulmonary non-small cell and neuroendocrine carcinomas. Appl Immunohistochem Mol Morphol; 2010 Jan;18(1):55-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sox2 expression in pulmonary non-small cell and neuroendocrine carcinomas.
  • Sox2 is a transcription factor that regulates embryonic stem cell pluripotency and drives commitment of airway precursor cells to basal-type and neuroendocrine cells in the developing lung.
  • Immunohistochemistry for Sox2, p63, CK5/6, and thyroid transcription factor-1 was performed on 121 tumors, including 34 adenocarcinomas (ACA), 32 squamous cell carcinomas (SCC), 14 typical carcinoids, 12 atypical carcinoids, 14 large cell neuroendocrine carcinomas, and 15 small cell carcinomas.
  • Among non-small cell lung carcinoma overall, there was a significant association between Sox2+/p63- expression and high-grade histology (P = 0.02).
  • Sox2 is highly expressed in concert with p63 in most SCC, but may also influence tumor differentiation in both non-small cell lung carcinomas and pulmonary neuroendocrine tumors.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661786.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins; 0 / Nuclear Proteins; 0 / SOX2 protein, human; 0 / SOXB1 Transcription Factors; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


42. Stewart CJ, Crook ML, Leung YC, Platten M: Expression of cell cycle regulatory proteins in endometrial adenocarcinoma: variations in conventional tumor areas and in microcystic, elongated and fragmented glands. Mod Pathol; 2009 May;22(5):725-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cell cycle regulatory proteins in endometrial adenocarcinoma: variations in conventional tumor areas and in microcystic, elongated and fragmented glands.
  • Endometrial adenocarcinomas may show a distinctive pattern of invasion characterized by the presence of microcystic, elongated and fragmented glands, often most evident along the advancing tumor margin.
  • In this study, we have examined immunoreactivity for the cell cycle regulatory proteins cyclin D1, p16 and beta-catenin in 22 endometrial carcinomas, specifically comparing the results in conventional tumor areas and in foci in which the glands exhibited microcystic, elongated and fragmented appearances.
  • Cyclin D1 and beta-catenin predominantly stained cells at the peripheral or basal aspect of the conventional glands, whereas p16 was more uniformly expressed centrally.
  • The heterogeneous expression of cell cycle regulatory proteins within endometrial adenocarcinoma illustrates the importance of assessing microanatomical variations in immunoreactivity, particularly at the advancing margin of tumors.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cell Cycle Proteins / biosynthesis. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19270644.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / beta Catenin; 136601-57-5 / Cyclin D1
  •  go-up   go-down


43. Lisovsky M, Dresser K, Baker S, Fisher A, Woda B, Banner B, Lauwers GY: Cell polarity protein Lgl2 is lost or aberrantly localized in gastric dysplasia and adenocarcinoma: an immunohistochemical study. Mod Pathol; 2009 Jul;22(7):977-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell polarity protein Lgl2 is lost or aberrantly localized in gastric dysplasia and adenocarcinoma: an immunohistochemical study.
  • The diagnosis of gastric epithelial dysplasia, a precursor lesion of gastric adenocarcinoma, is hindered by interobserver variability and by its resemblance to regenerative changes.
  • Loss of cell polarity, a histological feature of gastric epithelial dysplasia, may be difficult to ascertain, especially in the setting of inflammation or injury.
  • A biomarker of cell polarity could be useful in diagnosis of dysplasia, but has not been reported.
  • The Lethal giant larvae (lgl) gene controls apical-basal polarity of epithelial cells in Drosophila, and has properties of a tumor-suppressor gene.
  • The goal of our study was to test the hypothesis that Lgl2 protein expression and/or localization are disrupted in gastric epithelial dysplasia and adenocarcinoma.
  • Routinely processed pathology specimens including 94 benign mucosae of digestive organs, in addition to 36 reactive gastropathy, 57 gastric epithelial dysplasia, and 77 gastric adenocarcinomas, were immunostained for Lgl2 protein.
  • All but one case each of gastric epithelial dysplasia and adenocarcinoma showed either complete loss of anti-Lgl2 immunoreactivity or diffuse, mostly weak, cytoplasmic staining.
  • Complete loss of immunoreactivity was significantly more often observed in diffuse-type than in intestinal-type adenocarcinomas (79 vs 48%, respectively).
  • Our data suggest that Lgl2 expression is either aberrantly localized or lost in gastric epithelial dysplasia and adenocarcinoma, whereas it is maintained in reactive gastric mucosa.
  • We propose that Lgl2 may be a potential marker to rule out gastric epithelial dysplasia and adenocarcinoma in diagnostic specimens.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cytoskeletal Proteins / metabolism. Gastric Mucosa / metabolism. Precancerous Conditions / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Cell Polarity. Female. Fluorescent Antibody Technique, Direct. Humans. Immunoenzyme Techniques. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407852.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / Hugl-2 protein, human
  •  go-up   go-down


44. Long KB, Hornick JL: SOX2 is highly expressed in squamous cell carcinomas of the gastrointestinal tract. Hum Pathol; 2009 Dec;40(12):1768-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SOX2 is highly expressed in squamous cell carcinomas of the gastrointestinal tract.
  • SOX2 is a high-mobility group box embryonic stem cell transcription factor that is expressed in the developing foregut and normal gastric epithelium and is downregulated in intestinal metaplasia of the stomach and esophagus.
  • In addition, SOX2 colocalizes with p63 in the basal layer and plays a critical role in the maintenance of the stratified squamous epithelium of the esophagus.
  • SOX2 expression in squamous cell carcinomas of the gastrointestinal tract has not been previously evaluated.
  • The purpose of this study was to determine whether SOX2 is differentially expressed in squamous cell carcinomas versus adenocarcinomas of the esophagus and rectum/anal canal and to compare its expression to p63, cytokeratin 5/6, and CDX2.
  • In total, 93 tumors were evaluated: 26 esophageal squamous cell carcinomas, 23 esophageal adenocarcinomas, 21 squamous cell carcinomas of the anal canal, and 23 rectal adenocarcinomas.
  • SOX2 was expressed in 81% of esophageal squamous cell carcinomas and 91% of anal canal squamous cell carcinomas, compared to 13% and 17% of esophageal and rectal adenocarcinomas, respectively. p63 was expressed in 96% of esophageal squamous cell carcinomas and 100% of anal canal squamous cell carcinomas; the single squamous cell carcinoma negative for p63 was strongly positive for SOX2.
  • Cytokeratin 5/6 was expressed in most esophageal and anal canal squamous cell carcinomas, but was also positive in 43% of esophageal adenocarcinomas and 13% of rectal adenocarcinomas.
  • In summary, SOX2 is preferentially expressed in squamous cell carcinomas of the esophagus and anal canal compared to adenocarcinomas from these sites.
  • SOX2 may be useful in an immunohistochemical panel to differentiate between squamous cell carcinomas and adenocarcinomas of the gastrointestinal tract.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / metabolism. Gastrointestinal Neoplasms / metabolism. SOXB1 Transcription Factors / biosynthesis
  • [MeSH-minor] Adenocarcinoma / metabolism. Diagnosis, Differential. Homeodomain Proteins / biosynthesis. Humans. Immunohistochemistry. Keratin-5 / biosynthesis. Keratin-6 / biosynthesis. Membrane Proteins / biosynthesis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19716157.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / CKAP4 protein, human; 0 / Homeodomain Proteins; 0 / Keratin-5; 0 / Keratin-6; 0 / Membrane Proteins; 0 / SOX2 protein, human; 0 / SOXB1 Transcription Factors
  •  go-up   go-down


45. Cruz-Monserrate Z, Qiu S, Evers BM, O'Connor KL: Upregulation and redistribution of integrin alpha6beta4 expression occurs at an early stage in pancreatic adenocarcinoma progression. Mod Pathol; 2007 Jun;20(6):656-67
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulation and redistribution of integrin alpha6beta4 expression occurs at an early stage in pancreatic adenocarcinoma progression.
  • Pancreatic adenocarcinomas are highly invasive cancers for reasons that are currently unclear.
  • Here we sought to determine if the proinvasive integrin alpha6beta4 may be related to pancreatic adenocarcinoma tumor progression.
  • Expression of integrin alpha6beta4 was analyzed via immunohistochemistry for the beta4 subunit in normal pancreas, pancreatic intraepithelial neoplasia (PanIN) lesions, pancreatic adenocarcinomas and chronic pancreatitis.
  • In normal pancreatic ducts, integrin alpha6beta4 was noted only at the cell's basal interface with the basement membrane.
  • In pancreatic adenocarcinomas, 92% (104/113) demonstrated overexpression of integrin alpha6beta4 and altered localization to the cytoplasm and membranous regions.
  • We conclude that integrin alpha6beta4 is expressed only on the basal surface of ductal cells in normal pancreas and chronic pancreatitis.
  • During pancreatic adenocarcinoma progression, the alpha6beta4 integrin is dramatically overexpressed and displays altered localization at the earliest stages of PanIN, thus representing an early event in pancreatic adenocarcinoma progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17415382.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / F31 CA106201; United States / NCI NIH HHS / CA / R21 CA102125; United States / NCI NIH HHS / CA / R21-CA102125
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Integrin alpha6beta4
  • [Other-IDs] NLM/ NIHMS517144; NLM/ PMC4697742
  •  go-up   go-down


46. Liu YL, Matsuzaki T, Nakazawa T, Murata S, Nakamura N, Kondo T, Iwashina M, Mochizuki K, Yamane T, Takata K, Katoh R: Expression of aquaporin 3 (AQP3) in normal and neoplastic lung tissues. Hum Pathol; 2007 Jan;38(1):171-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the expression of AQP3 in normal and neoplastic lung tissues, we studied a series of 149 lung carcinoma tissues and 2 cell lines by immunohistochemistry, Western blotting, and reverse transcriptase-polymerase chain reaction.
  • In normal lung tissues, immunohistochemical expression of AQP3 was demonstrated in bronchial basal cells, alveolar type II cells, bronchiolar epithelial cells, and secretory cells of submucosal glands.
  • In lung carcinomas, AQP3 expression was observed in 59 (70.2%) of 84 adenocarcinomas.
  • Squamous cell carcinoma and large cell carcinoma had rather low positive ratios (35.8% and 13.4%, respectively).
  • No AQP3 expression was demonstrated in small cell carcinoma, pleomorphic carcinoma, or metastatic colon adenocarcinoma.
  • In adenocarcinomas, AQP3 was detected in all tumors of bronchioloalveolar subtype.
  • In addition, AQP3 expression was related to tumor differentiation and clinical stage in adenocarcinomas.
  • Western blotting and reverse transcriptase-polymerase chain reaction analyses confirmed the expression of AQP3 protein and messenger RNA in cell lines and tissues of lung adenocarcinoma.
  • In addition, lung carcinomas, especially adenocarcinomas, can produce AQP3, possibly in connection with their functional and/or biological nature, although the detailed mechanism of AQP3 expression in lung carcinomas remains to be clarified.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Blotting, Western. Cell Line, Tumor. Female. Gene Expression. Humans. Immunohistochemistry. Male. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17056099.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 158801-98-0 / Aquaporin 3
  •  go-up   go-down


47. Tamiolakis D, Proimos E, Perogamvrakis GE, Skoulakis CE, Georgiou GC, Papadakis CE: Brushing cytology in cutaneous lesions of the head and neck. J Laryngol Otol; 2007 Jul;121(7):676-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Cytological analysis identified 63 out of 64 histologically documented malignant tumours (60 primary basal cell and squamous cell carcinomas and three metastatic adenocarcinomas), and 21 out of 22 benign lesions.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Head and Neck Neoplasms / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Cytological Techniques. Diagnosis, Differential. Endometriosis / pathology. False Negative Reactions. False Positive Reactions. Female. Humans. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17403275.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


48. Cross SS, Lippitt J, Mitchell A, Hollingsbury F, Balasubramanian SP, Reed MW, Eaton C, Catto JW, Hamdy F, Winder SJ: Expression of beta-dystroglycan is reduced or absent in many human carcinomas. Histopathology; 2008 Nov;53(5):561-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression of beta-dystroglycan was absent or markedly reduced in 100% of oesophageal adenocarcinomas, 97% of colonic cancers, 100% of transitional cell carcinomas of the urothelium and 94% of breast cancers.
  • The only cancers that showed retention of beta-dystroglycan expression were cutaneous basal cell carcinomas.
  • [MeSH-minor] Cell Line, Tumor. Epithelium / metabolism. Female. Humans. Immunohistochemistry. Male. Models, Biological. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18983465.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MRC/ G0500966; United Kingdom / Medical Research Council / / 58152
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 146888-27-9 / Dystroglycans
  •  go-up   go-down


49. Kamei Y, Kito K, Takeuchi T, Imai Y, Murase R, Ueda N, Kobayashi N, Abe Y: Human scribble accumulates in colorectal neoplasia in association with an altered distribution of beta-catenin. Hum Pathol; 2007 Aug;38(8):1273-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In Drosophila, genetic studies identified 3 neoplastic tumor suppressor genes (nTSGs), and a loss of nTSGs has been shown to result in a disruption of apical-basal polarity and neoplastic growth in epithelial cells.
  • In 50 cases of colorectal adenomas and adenocarcinomas, the accumulation of hScrib protein was commonly observed in comparison with the adjacent normal epithelia.
  • In an immunofluorescence analysis on cultured cell lines, the loss of membranous staining of hScrib was observed according to the cytoplasmic translocation of beta-catenin.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / pathology. Membrane Proteins / metabolism. Tumor Suppressor Proteins / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Female. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509663.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Membrane Proteins; 0 / SCRIB protein, human; 0 / Tumor Suppressor Proteins; 0 / beta Catenin
  •  go-up   go-down


50. Seigne C, Fontanière S, Carreira C, Lu J, Tong WM, Fontanière B, Wang ZQ, Zhang CX, Frappart L: Characterisation of prostate cancer lesions in heterozygous Men1 mutant mice. BMC Cancer; 2010;10:395
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Six Men1+/- mice (12.8%) developed prostate cancer, including two adenocarcinomas and four in situ carcinomas, while none of the control mice developed cancerous lesions.
  • Using immunostaining for the androgen receptor and p63, a basal epithelial cell marker, we demonstrated that the menin-negative prostate cancer cells did not display p63 expression and that the androgen receptor was expressed but more heterogeneous in these lesions.
  • Furthermore, our data showed that the expression of the cyclin-dependent kinase inhibitor CDKN1B (p27), a Men1 target gene known to be inactivated during prostate cell tumorigenesis, was notably decreased in the prostate cancers that developed in the mutant mice.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Loss of Heterozygosity. Prostatic Neoplasms / genetics. Prostatic Neoplasms / pathology. Proto-Oncogene Proteins / physiology


51. Steiner FA, Hong JA, Fischette MR, Beer DG, Guo ZS, Chen GA, Weiser TS, Kassis ES, Nguyen DM, Lee S, Trepel JB, Schrump DS: Sequential 5-Aza 2'-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells. Oncogene; 2005 Mar 31;24(14):2386-97
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In both cell lines, sequential DAC/DP treatment induced expression of tissue factor pathway inhibitor-2 (TFPI-2), an inhibitor of Factor VII: tissue factor signal transduction known to diminish the malignant phenotype of cancer cells.
  • TFPI-2 expression was diminished or absent in 16 of 32 cell lines established from thoracic malignancies.
  • Sequential DAC/DP treatment induced TFPI-2 in cancer cells deficient for TFPI-2 expression in the basal state.
  • TFPI-2 promoter methylation was observed in one of five pulmonary adenocarcinomas, and seven of seven esophageal adenocarcinomas, but not corresponding normal tissues.
  • [MeSH-minor] Base Sequence. Cell Line, Tumor. DNA Primers. Humans

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735751.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Depsipeptides; 0 / Glycoproteins; 0 / tissue-factor-pathway inhibitor 2; 776B62CQ27 / decitabine; CX3T89XQBK / romidepsin; M801H13NRU / Azacitidine
  •  go-up   go-down


52. Peehl DM: Primary cell cultures as models of prostate cancer development. Endocr Relat Cancer; 2005 Mar;12(1):19-47
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cell cultures as models of prostate cancer development.
  • Current abilities to culture cells from normal tissues, from premalignant dysplastic lesions (prostatic intraepithelial neoplasia), from primary adenocarcinomas, and from metastases are described.
  • Evidence for representation of the interrelated cells of the normal prostatic epithelium--stem cells, basal epithelial cells, secretory epithelial cells, transit amplifying cells and neuroendocrine cells--in primary cultures is presented.
  • While the behavior of normal primary cultures is often used as a basis for comparison with established, immortal prostate cancer cell lines, the most informative studies are performed with donor-matched pairs of normal and malignant primary cultures, grown under identical conditions.
  • Challenges that remain to be addressed if the full potential of primary cultures as a model system is to be realized include isolation, culture and characterization of stem cells, improved methodology to induce or maintain a fully differentiated, androgen-responsive phenotype, and identification of cell surface antigens or other markers with which to purify pure populations of live cancer or premalignant cells apart from non-malignant epithelial cells prior to culture.
  • [MeSH-major] Adenocarcinoma / pathology. Models, Biological. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15788637.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 230
  •  go-up   go-down


53. Teissedre B, Pinderhughes A, Incassati A, Hatsell SJ, Hiremath M, Cowin P: MMTV-Wnt1 and -DeltaN89beta-catenin induce canonical signaling in distinct progenitors and differentially activate Hedgehog signaling within mammary tumors. PLoS One; 2009;4(2):e4537
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A significant proportion of human breast cancer is associated with loss of secreted Wnt antagonists and mice expressing MMTV-Wnt1 and MMTV-DeltaN89beta-catenin develop mammary adenocarcinomas.
  • Using axin2/conductin reporter genes we show that MMTV-Wnt1 and MMTV-DeltaN89beta-catenin activate canonical Wnt signaling within distinct cell-types.
  • In contrast, MMTV-Wnt1 induced canonical signaling in K14(+) basal cells with CD24/CD49f profiles characteristic of two distinct stem/progenitor cell-types.
  • MMTV-Wnt1 produced additional profound effects on multiple cell-types that correlated with focal activation of the Hedgehog pathway.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Biol. 1995 Aug;170(2):553-63 [7649383.001]
  • [Cites] Tissue Cell. 1997 Apr;29(2):239-53 [9149446.001]
  • [Cites] Cell. 1998 Nov 25;95(5):605-14 [9845363.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jan;10(1):75-86 [15886888.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):499-508 [16107313.001]
  • [Cites] Nature. 2006 Feb 23;439(7079):993-7 [16395311.001]
  • [Cites] Development. 2006 Sep;133(18):3661-70 [16914490.001]
  • [Cites] J Biol Chem. 2006 Nov 17;281(46):35081-7 [16973609.001]
  • [Cites] J Cell Biol. 2007 Jan 1;176(1):19-26 [17190790.001]
  • [Cites] Nat Cell Biol. 2007 Feb;9(2):201-9 [17187062.001]
  • [Cites] Development. 2007 Mar;134(6):1231-42 [17287253.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5895-900 [17392427.001]
  • [Cites] J Cell Biol. 2007 Apr 9;177(1):87-101 [17420292.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2007 Sep;12(2-3):163-73 [17623270.001]
  • [Cites] Development. 2007 Oct;134(20):3723-32 [17804598.001]
  • [Cites] Development. 2007 Oct;134(20):3703-12 [17881490.001]
  • [Cites] Development. 2007 Nov;134(21):3929-39 [17898001.001]
  • [Cites] Nature. 2007 Oct 25;449(7165):1003-7 [17934449.001]
  • [Cites] J Biol Chem. 2007 Dec 7;282(49):36090-101 [17928300.001]
  • [Cites] Stem Cells. 2008 Feb;26(2):364-71 [17975224.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):650-3 [18385740.001]
  • [Cites] Stem Cells. 2008 May;26(5):1253-64 [18292212.001]
  • [Cites] Development. 1999 Nov;126(22):5181-93 [10529434.001]
  • [Cites] Genes Dev. 2000 Mar 15;14(6):650-4 [10733525.001]
  • [Cites] J Cell Biol. 2001 Apr 30;153(3):555-68 [11331306.001]
  • [Cites] Cell. 2001 May 18;105(4):533-45 [11371349.001]
  • [Cites] Oncogene. 2001 Sep 13;20(41):5810-7 [11593386.001]
  • [Cites] J Cell Biol. 2001 Dec 10;155(6):1055-64 [11739413.001]
  • [Cites] Mol Cell Biol. 2002 Feb;22(4):1172-83 [11809808.001]
  • [Cites] Mol Cell Biol. 2002 Feb;22(4):1184-93 [11809809.001]
  • [Cites] Dev Biol. 2002 May 1;245(1):42-56 [11969254.001]
  • [Cites] Dev Cell. 2002 May;2(5):643-53 [12015971.001]
  • [Cites] Development. 2002 Oct;129(20):4753-61 [12361967.001]
  • [Cites] Breast Cancer Res. 2003;5(1):R1-8 [12559051.001]
  • [Cites] J Cell Sci. 2003 Mar 15;116(Pt 6):1137-49 [12584256.001]
  • [Cites] Bioessays. 2003 Apr;25(4):317-25 [12655639.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1906-13 [12702582.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11400-5 [13679587.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2003 Apr;8(2):145-58 [14635791.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15853-8 [14668450.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4158-63 [15020770.001]
  • [Cites] Cell. 1988 Nov 18;55(4):619-25 [3180222.001]
  • [Cites] J Cutan Pathol. 1991 Dec;18(6):436-9 [1723081.001]
  • [Cites] Dev Biol. 1993 Jan;155(1):87-96 [8416847.001]
  • [Cites] Genes Dev. 1994 Nov 15;8(22):2691-703 [7958926.001]
  • [Cites] Hum Mol Genet. 2008 Jul 15;17(14):2118-31 [18397875.001]
  • [Cites] Nature. 2008 Sep 18;455(7211):406-10 [18754008.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7711-7 [18829523.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):281-3 [18835029.001]
  • [Cites] Nat Genet. 2008 Sep;40(9):1130-5 [19165927.001]
  • [Cites] Nature. 2006 Jan 5;439(7072):84-8 [16397499.001]
  • [ErratumIn] PLoS ONE. 2009;4(3). doi: 10.1371/annotation/3706d475-e082-4be6-b328-7d8aea02b986
  • (PMID = 19225568.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / F31CA130137; United States / NIGMS NIH HHS / GM / R01 GM047429; United States / NIGMS NIH HHS / GM / NIH-R01-GM47429; United States / NCI NIH HHS / CA / NIH-R21-CA129905; United States / NCI NIH HHS / CA / F31 CA130137; United States / NCI NIH HHS / CA / F31 CA119940; United States / NCI NIH HHS / CA / F31CA119940-02
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / Wnt1 Protein; 0 / Wnt1 protein, mouse; 0 / beta Catenin
  • [Other-IDs] NLM/ PMC2639708
  •  go-up   go-down


54. Tanaka Y, Aleksunes LM, Goedken MJ, Chen C, Reisman SA, Manautou JE, Klaassen CD: Coordinated induction of Nrf2 target genes protects against iron nitrilotriacetate (FeNTA)-induced nephrotoxicity. Toxicol Appl Pharmacol; 2008 Sep 15;231(3):364-73
Hazardous Substances Data Bank. IRON (3+) NTA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic exposure of FeNTA leads to a high incidence of renal adenocarcinomas in rodents.
  • NF-E2-related factor 2 (Nrf2) is a transcription factor that is activated by oxidative stress and electrophiles, and regulates the basal and inducible expression of numerous detoxifying and antioxidant genes.

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRILOTRIACETIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1980 Sep;77(9):5216-20 [6933553.001]
  • [Cites] Histochemistry. 1979 Sep;63(2):245-51 [500408.001]
  • [Cites] Am J Pathol. 1986 May;123(2):343-50 [3706495.001]
  • [Cites] Cancer Res. 1987 Apr 1;47(7):1867-9 [3815378.001]
  • [Cites] J Biol Chem. 1992 Oct 25;267(30):21894-900 [1400499.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2616-20 [8146163.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):5987-91 [8016102.001]
  • [Cites] Chem Res Toxicol. 1995 Jan-Feb;8(1):34-9 [7703364.001]
  • [Cites] Arch Biochem Biophys. 1996 May 1;329(1):39-46 [8619633.001]
  • [Cites] Lab Invest. 1997 Mar;76(3):365-74 [9121119.001]
  • [Cites] J Am Soc Nephrol. 1997 Aug;8(8):1213-21 [9259347.001]
  • [Cites] J Biol Chem. 1999 Aug 20;274(34):23787-93 [10446139.001]
  • [Cites] J Nutr. 2004 Dec;134(12 Suppl):3499S-3506S [15570060.001]
  • [Cites] Toxicol Sci. 2005 Jan;83(1):44-52 [15496496.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4789-98 [15930299.001]
  • [Cites] Drug Metab Dispos. 2005 Jul;33(7):947-55 [15802388.001]
  • [Cites] Biochem Pharmacol. 2005 Oct 1;70(7):1088-95 [16099435.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):221-9 [16354693.001]
  • [Cites] Toxicol Sci. 2006 Feb;89(2):370-9 [16177239.001]
  • [Cites] Biochem J. 2006 May 1;395(3):599-609 [16426233.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Dec 29;351(4):883-9 [17097057.001]
  • [Cites] Neurotoxicology. 2006 Dec;27(6):1094-100 [16959318.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Feb 9;353(2):389-93 [17178108.001]
  • [Cites] Mol Pharmacol. 2007 Mar;71(3):817-25 [17151289.001]
  • [Cites] Hepatology. 2007 Nov;46(5):1597-610 [17668877.001]
  • [Cites] Toxicol Pathol. 2008 Feb;36(2):353-61 [18364461.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14960-5 [8962164.001]
  • [Cites] J Biol Chem. 2000 May 26;275(21):16023-9 [10821856.001]
  • [Cites] Toxicol Sci. 2001 Jan;59(1):169-77 [11134556.001]
  • [Cites] Kidney Int. 2001 Oct;60(4):1343-53 [11576348.001]
  • [Cites] Am J Respir Cell Mol Biol. 2002 Feb;26(2):175-82 [11804867.001]
  • [Cites] Methods Enzymol. 2002;348:182-90 [11885271.001]
  • [Cites] Biochem J. 2002 Jun 1;364(Pt 2):563-70 [12023900.001]
  • [Cites] Free Radic Biol Med. 2002 Aug 1;33(3):370-8 [12126759.001]
  • [Cites] Am J Physiol Renal Physiol. 2003 Apr;284(4):F743-52 [12453873.001]
  • [Cites] Arch Biochem Biophys. 2003 Mar 15;411(2):243-50 [12623073.001]
  • [Cites] Toxicol Lett. 2003 Apr 11;140-141:133-43 [12676459.001]
  • [Cites] Free Radic Biol Med. 2003 May 15;34(10):1236-42 [12726911.001]
  • [Cites] Biofactors. 2003;17(1-4):103-14 [12897433.001]
  • [Cites] Redox Rep. 2003;8(3):163-7 [12935314.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Oct 24;310(3):824-9 [14550278.001]
  • [Cites] Toxicol Appl Pharmacol. 1985 Feb;77(2):267-74 [3975899.001]
  • (PMID = 18617210.001).
  • [ISSN] 1096-0333
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / RR021940; United States / NIEHS NIH HHS / ES / R01 ES009716; United States / NIEHS NIH HHS / ES / R01 ES009649-07; United States / NCRR NIH HHS / RR / P20 RR021940-03; United States / NIEHS NIH HHS / ES / T32 ES007079; United States / NIEHS NIH HHS / ES / ES009649-07; United States / NIEHS NIH HHS / ES / ES007079-27; United States / NIEHS NIH HHS / ES / R01 ES009649; United States / NIEHS NIH HHS / ES / T32 ES007079-27; United States / NCRR NIH HHS / RR / P20 RR021940; United States / NIEHS NIH HHS / ES / ES009716-08; United States / NIEHS NIH HHS / ES / ES-09716; United States / NIEHS NIH HHS / ES / ES-07079; United States / NIEHS NIH HHS / ES / R01 ES009716-08; None / None / / P20 RR021940-03; United States / NIEHS NIH HHS / ES / ES-09649
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ferric Compounds; 0 / NF-E2-Related Factor 2; KA90006V9D / Nitrilotriacetic Acid; Z3U5ED15B9 / ferric nitrilotriacetate
  • [Other-IDs] NLM/ NIHMS76279; NLM/ PMC2582522
  •  go-up   go-down


55. Yee DS, Narula N, Ramzy I, Boker J, Ahlering TE, Skarecky DW, Ornstein DK: Reduced annexin II protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer. Arch Pathol Lab Med; 2007 Jun;131(6):902-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Foci with normal prostatic glands, atrophic glands, basal cell hyperplasia, high-grade prostatic intraepithelial neoplasia, and prostatic adenocarcinoma were evaluated.
  • RESULTS: Annexin II expression was present in more than 50% of glands in most (>85%) samples of benign prostatic epithelium, atrophic glands, and basal cell hyperplasia.
  • In high-grade prostatic intraepithelial neoplasia, annexin II staining was markedly reduced in epithelial cells but not in basal cells.
  • Annexin II was absent or focally present in moderately differentiated adenocarcinoma but was retained in poorly differentiated adenocarcinomas.
  • CONCLUSIONS: Reduced annexin II expression may be a useful diagnostic biomarker to help identify small foci of moderately differentiated adenocarcinoma on needle core biopsy specimens since it is consistently expressed in benign prostatic glands.
  • Re-expression of annexin II in poorly differentiated adenocarcinoma may provide prognostic information.
  • [MeSH-major] Adenocarcinoma / metabolism. Annexin A2 / metabolism. Prostate / metabolism. Prostatic Intraepithelial Neoplasia / metabolism. Prostatic Neoplasms / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17550317.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A2; 0 / Biomarkers, Tumor
  •  go-up   go-down


56. Lovrić E, Gatalica Z, Eyzaguirre E, Kruslin B: Expression of maspin and glutathionine-S-transferase-pi in normal human prostate and prostatic carcinomas. Appl Immunohistochem Mol Morphol; 2010 Oct;18(5):429-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Maspin and GST-pi were strongly and consistently coexpressed in the cytoplasm of basal cells of normal prostatic glands, whereas normal luminal cells were inconsistently weakly positive.
  • Prostatic adenocarcinomas overexpressed maspin in 27/34 cases (79%).
  • CONCLUSION: Consistent coexpression of maspin and GST-pi was observed in basal cells of the prostatic glands, which could be used as an additional immunohistochemical test in the evaluation of prostatic malignancy.
  • Prostatic adenocarcinomas express maspin in an aberrant nuclear distribution without coexpresion of GST-pi.
  • These results indicate a deregulation of expression of maspin and GST-pi in prostatic adenocarcinomas.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20453817.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / SERPIN-B5; 0 / Serpins; EC 2.5.1.18 / Glutathione S-Transferase pi
  •  go-up   go-down


57. Heitland W: [Diagnosis and therapy for anal carcinoma]. Chirurg; 2008 Feb;79(2):183-91; quiz 192
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and therapy for anal carcinoma].
  • Of all carcinomas in the anal canal, 75-80% are squamous cell carcinomas-the remaining 25% being adenocarcinomas.
  • Carcinomas of the anal margin are to be differentiated from basal cell carcinomas and Paget's and Bowen's diseases.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1984 Aug 1;54(3):411-5 [6329504.001]
  • [Cites] J Gastrointest Surg. 2001 Jul-Aug;5(4):383-7 [11985979.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):45-51 [12504657.001]
  • [Cites] Dis Colon Rectum. 2005 Jan;48(1):16-22 [15690652.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Dis Colon Rectum. 2004 Jul;47(7):1136-44 [15164245.001]
  • [Cites] World J Surg. 2005 Nov;29(11):1452-7 [16222445.001]
  • [Cites] Dis Colon Rectum. 2005 Sep;48(9):1742-51 [15991058.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2062-8 [6435851.001]
  • [Cites] Colorectal Dis. 2006 Feb;8(2):124-9 [16412072.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):479-85 [15890590.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):478-83 [17103253.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Am J Surg. 1985 Jan;149(1):95-101 [3966647.001]
  • [Cites] Ann Surg. 1976 Oct;184(4):422-8 [189707.001]
  • [Cites] Ann Surg. 1994 Jul;220(1):40-9 [8024357.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • (PMID = 18227955.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


58. Ozawa MG, Yao VJ, Chanthery YH, Troncoso P, Uemura A, Varner AS, Kasman IM, Pasqualini R, Arap W, McDonald DM: Angiogenesis with pericyte abnormalities in a transgenic model of prostate carcinoma. Cancer; 2005 Nov 15;104(10):2104-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Previous studies of the TRansgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model vasculature suggest that, as tumors develop, vessels invade the glandular epithelium.
  • The authors used a new approach to characterize morphologic and architectural changes of blood vessels and pericytes during tumor development in TRAMP mice.
  • METHODS: Eighty-micron cryostat sections of normal prostate and three histopathologic stages of TRAMP tumor sections, classified by epithelial cell E-cadherin immunoreactivity, were immunostained with vascular endothelial cell and pericyte receptor antibodies and evaluated by confocal microscopy.
  • In the prostatic intraepithelial neoplasia (PIN) stage, vessels accompanied epithelial cell protrusions into the ductule lumen but remained in the connective tissue at the basal side of the epithelium.
  • Angiogenic blood vessels from poorly differentiated adenocarcinomas were tortuous, variable in caliber, and lacked the normal hierarchy.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society
  • (PMID = 16208706.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL-24136; United States / NHLBI NIH HHS / HL / P01 HL024136; United States / NHLBI NIH HHS / HL / R01 HL059157; United States / NCI NIH HHS / CA / P50 CA90270; United States / NHLBI NIH HHS / HL / HL-59157
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins
  •  go-up   go-down


59. Sato T, Murakumo Y, Hagiwara S, Jijiwa M, Suzuki C, Yatabe Y, Takahashi M: High-level expression of CD109 is frequently detected in lung squamous cell carcinomas. Pathol Int; 2007 Nov;57(11):719-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-level expression of CD109 is frequently detected in lung squamous cell carcinomas.
  • CD109 is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein, which is a member of the alpha2-macroglobulin/C3, C4, C5 family of thioester-containing proteins.
  • Herein it is reported that the CD109 protein is preferentially expressed in lung squamous cell carcinomas compared with other types of lung carcinoma including adenocarcinomas, large cell carcinomas and small cell carcinomas.
  • Immunohistochemical staining of surgically resected lung specimens using an anti-CD109 antibody detected CD109 expression in basal cells of bronchial and bronchiolar epithelia and myoepithelial cells of bronchial secretary glands, but not in bronchial and bronchiolar apical epithelial cells and alveolar epithelial cells.
  • Furthermore, the CD109 immunoreactivity was observed in squamous cell carcinomas at a high frequency compared with other types of lung carcinoma.
  • Although the detailed function of CD109 protein is unclear, these results suggest that CD109 expression may play a role in the development of lung squamous cell carcinoma.
  • [MeSH-major] Antigens, CD / metabolism. Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / metabolism. Lung Neoplasms / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Blotting, Western. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / pathology. Carcinoma, Small Cell / metabolism. Carcinoma, Small Cell / pathology. Female. GPI-Linked Proteins. Gene Expression. Humans. Immunohistochemistry. Male. Middle Aged. RNA, Small Interfering

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922683.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CD109 protein, human; 0 / GPI-Linked Proteins; 0 / Neoplasm Proteins; 0 / RNA, Small Interfering
  •  go-up   go-down


60. Vesely DL: Cardiac and renal hormones: anticancer effects in vitro and in vivo. J Investig Med; 2009 Jan;57(1):22-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Four cardiovascular hormones, ie, vessel dilator, long-acting natriuretic peptide, kaliuretic peptide, and atrial natriuretic peptide each at 1 mmol/L, decrease up to 97% of human breast, ovarian, pancreatic, colon, kidney, and prostate adenocarcinoma cells, as well as small cell and squamous cell lung cancer cells within 24 hours.
  • RESULTS: These cardiac hormones completely stop the growth of human pancreatic adenocarcinomas in athymic mice and decrease their tumor volume by 49%, 28%, and 11%, respectively, in 1 week.
  • When these cardiac hormones are given subcutaneously for 1 month via osmotic pumps with the pumps changed weekly, up to 80% of the human pancreatic adenocarcinomas growing in athymic mice can be completely eliminated.
  • CONCLUSIONS: The cardiac hormones' anticancer mechanism of action(s) include a strong inhibition of mitogen (epidermal growth factor and insulin) activated extracellular signal-regulated kinases (ERK) 1/2 and as well as inhibition of basal extracellular-signal regulated kinase 1/2 and upstream MEK 1/2 phosphorylation.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19092678.001).
  • [ISSN] 1081-5589
  • [Journal-full-title] Journal of investigative medicine : the official publication of the American Federation for Clinical Research
  • [ISO-abbreviation] J. Investig. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Natriuretic Peptides
  • [Number-of-references] 76
  •  go-up   go-down


61. Went PT, Sauter G, Oberholzer M, Bubendorf L: Abundant expression of AMACR in many distinct tumour types. Pathology; 2006 Oct;38(5):426-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Alpha-methylacyl-CoA racemase (AMACR), a mitochondrial and peroxisomal enzyme, is a valuable tool to confirm the diagnosis of prostate cancer, especially if combined with basal cell markers.
  • RESULTS: Microarray analysis revealed that tumours with prominent AMACR expression included adenocarcinomas of the prostate (72%), hepatocellular carcinomas (77%), papillary renal cell carcinomas (70%), and colorectal adenocarcinomas (71%).
  • CONCLUSION: Taken together, the results indicate that AMACR is expressed in a wide variety of adenocarcinomas, and its diagnostic utility is restricted to specific areas.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Neoplasms / metabolism. Racemases and Epimerases / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17008281.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


62. Domingo-Domenech J, Mellado B, Ferrer B, Truan D, Codony-Servat J, Sauleda S, Alcover J, Campo E, Gascon P, Rovira A, Ross JS, Fernández PL, Albanell J: Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer; 2005 Nov 28;93(11):1285-94
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nuclear factor (NF)-kappaB/p65 regulates the transcription of a wide variety of genes involved in cell survival, invasion and metastasis.
  • We characterised by immunohistochemistry the expression of NF-kappaB/p65 protein in six histologically normal prostate, 13 high-grade prostatic intraepithelial neoplasia (PIN) and 86 prostate adenocarcinoma specimens.
  • Nuclear localisation of NF-kappaB was only seen in scattered basal cells in normal prostate glands.
  • In prostate adenocarcinomas, cytoplasmic NF-kappaB was detected in 57 (66.3%) specimens, and nuclear NF-kappaB (activated) in 47 (54.7%).
  • [MeSH-major] Adenocarcinoma / pathology. Cell Transformation, Neoplastic. NF-kappa B / biosynthesis. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Cell Nucleus. Cytoplasm / chemistry. Gene Expression Profiling. Humans. Immunohistochemistry. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Prognosis. Prostate-Specific Antigen. Risk Factors. Transcription Factor RelA / analysis. Transcription Factor RelA / biosynthesis. Transcription Factor RelA / pharmacokinetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2002 May 23;21(23):3727-38 [12032841.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):301-10 [12001991.001]
  • [Cites] Prostate. 2002 Aug 1;52(3):183-200 [12111695.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2369-77 [12114442.001]
  • [Cites] Trends Mol Med. 2002 Aug;8(8):385-9 [12127724.001]
  • [Cites] Mol Biol Cell. 2002 Aug;13(8):2933-45 [12181357.001]
  • [Cites] Cancer Detect Prev. 2002;26(3):229-37 [12269771.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):107-10 [12517785.001]
  • [Cites] Oncogene. 2003 Jan 9;22(1):50-8 [12527907.001]
  • [Cites] BJU Int. 2003 Mar;91(4):417-20 [12603426.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1359-64 [12649199.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2206-15 [12727841.001]
  • [Cites] Oncology. 2003;65(1):37-45 [12837981.001]
  • [Cites] Int J Oncol. 2003 Aug;23(2):317-23 [12851680.001]
  • [Cites] Oncogene. 2003 Jul 10;22(28):4314-32 [12853969.001]
  • [Cites] Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S75-85 [14600595.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7106-12 [14612503.001]
  • [Cites] J Cell Biochem. 2004 Jan 1;91(1):100-17 [14689584.001]
  • [Cites] Nat Rev Drug Discov. 2004 Jan;3(1):17-26 [14708018.001]
  • [Cites] Prostate. 2004 Feb 15;58(3):308-13 [14743471.001]
  • [Cites] Oncogene. 2004 Feb 26;23(8):1599-607 [14985701.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2466-72 [15073126.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):360-79 [14739906.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):349-60 [15122206.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 4;101(18):7112-7 [15118089.001]
  • [Cites] Br J Cancer. 2004 Jun 14;90(12):2312-6 [15150588.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10137-42 [15220474.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5036-43 [15289299.001]
  • [Cites] Am J Clin Pathol. 2003 Dec;120 Suppl:S85-100 [15298146.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5963-72 [15342375.001]
  • [Cites] Hum Pathol. 1992 Mar;23(3):273-9 [1555838.001]
  • [Cites] Cancer. 1994 Jul 1;74(1):104-14 [7516262.001]
  • [Cites] Annu Rev Immunol. 1996;14:649-83 [8717528.001]
  • [Cites] Annu Rev Immunol. 1998;16:225-60 [9597130.001]
  • [Cites] JAMA. 1999 May 5;281(17):1591-7 [10235151.001]
  • [Cites] J Pathol. 2004 Dec;204(5):569-77 [15481028.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8460-4 [15623625.001]
  • [Cites] Nat Immunol. 2005 May;6(5):439-45 [15843800.001]
  • [Cites] Oncogene. 1999 Nov 22;18(49):6938-47 [10602468.001]
  • [Cites] Oncogene. 1999 Dec 2;18(51):7389-94 [10602496.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2384-9 [10811114.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1969-77 [10815922.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2702-6 [10914713.001]
  • [Cites] Oncogene. 2001 Jul 12;20(31):4188-97 [11464285.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6500-10 [11522647.001]
  • [Cites] Oncogene. 2001 Nov 1;20(50):7342-51 [11704864.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):637-46 [11710679.001]
  • [Cites] J Natl Cancer Inst. 2001 Nov 21;93(22):1739-46 [11717335.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3037-44 [11753981.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4136-42 [11751513.001]
  • [Cites] J Cell Sci. 2002 Jan 1;115(Pt 1):141-51 [11801732.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(8):2862-70 [11909978.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):11116-25 [11799112.001]
  • [Cites] Oncogene. 2002 Jul 4;21(29):4490-7 [12085227.001]
  • (PMID = 16278667.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NF-kappa B; 0 / Transcription Factor RelA; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ PMC2361509
  •  go-up   go-down


63. Deng J, Fujimoto J, Ye XF, Men TY, Van Pelt CS, Chen YL, Lin XF, Kadara H, Tao Q, Lotan D, Lotan R: Knockout of the tumor suppressor gene Gprc5a in mice leads to NF-kappaB activation in airway epithelium and promotes lung inflammation and tumorigenesis. Cancer Prev Res (Phila); 2010 Apr;3(4):424-37
Guide to Pharmacology. gene/protein/disease-specific - Class C Orphans - overview and references .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Examination of normal lung tissue and tumors from 51 Gprc5a(+/+) (adenoma incidence, 9.8%; adenocarcinoma, 0%) and 38 Gprc5a(-/-) mice (adenoma, 63%; adenocarcinoma, 21%) revealed macrophage infiltration into lungs of 45% of the Gprc5a(-/-) mice and 8% of Gprc5a(+/+) mice and the direct association of macrophages with 42% of adenomas and 88% of adenocarcinomas in the knockout mice.
  • Studies with epithelial cells cultured from tracheas of Gprc5a(-/-) and Gprc5a(+/+) mice revealed that Gprc5a loss is associated with increased cell proliferation, resistance to cell death in suspension, and increased basal, tumor necrosis factor alpha-induced, and lipopolysaccharide-induced NF-kappaB activation, which were reversed partially in Gprc5a(-/-) adenocarcinoma cells by reexpression of Gprc5a.
  • Thus, Gprc5a loss enhances NF-kappaB activation in lung epithelial cells, leading to increased autocrine and paracrine interactions, cell autonomy, and enhanced inflammation, which may synergize in the creation of a tumor-promoting microenvironment.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pneumonia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 AACR.
  • [CommentIn] Cancer Prev Res (Phila). 2010 Apr;3(4):403-5 [20354166.001]
  • (PMID = 20354164.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P30 CA16672
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Receptors, G-Protein-Coupled
  •  go-up   go-down


64. Mhawech-Fauceglia P, Herrmann FR, Bshara W, Odunsi K, Terracciano L, Sauter G, Cheney RT, Groth J, Penetrante R, Mhawech-Fauceglia P: Friend leukaemia integration-1 expression in malignant and benign tumours: a multiple tumour tissue microarray analysis using polyclonal antibody. J Clin Pathol; 2007 Jun;60(6):694-700

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, it is also expressed in subsets of lymphoblastic lymphoma, Merkel cell carcinoma (MCC) and desmoplastic small round cell tumour (DSRCT).
  • RESULTS: FLI-1 was expressed in 46/62 EWS/PNETs, 2/3 olfactory neuroblastomas, 7/102 small cell carcinomas of the lung, 10/34 MCCs, 1/14 rhabdomyosarcoma, 19/132 non-Hodgkin's lymphomas, 2/3 DSRCTs, and in 53/74 benign and malignant vascular tumours.
  • In addition, 27/508 squamous cell carcinomas, 19/837 adenocarcinomas, 10/400 urothelial bladder cancers, 1/40 basal cell carcinomas, 3/29 liposarcomas, 1/40 glioblastoma multiforme and 9/29 medullar carcinomas of the breast expressed FLI-1.
  • Finally, the sensitivity and specificity of FLI-1 to distinguish EWS/PNET from other small round cell tumours (SRCTs) were 74.2% and 91.6%, respectively.
  • [MeSH-minor] Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / metabolism. Diagnosis, Differential. Humans. Immunoenzyme Techniques. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / metabolism. Neuroectodermal Tumors, Primitive / diagnosis. Neuroectodermal Tumors, Primitive / metabolism. Protein Array Analysis / methods. Sarcoma, Ewing / diagnosis. Sarcoma, Ewing / metabolism. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1061-6 [11474291.001]
  • [Cites] Am J Surg Pathol. 2000 Dec;24(12):1657-62 [11117787.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5747-54 [11607824.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):320-7 [11859203.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):994-1000 [14608532.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):122-8 [14745734.001]
  • [Cites] Mod Pathol. 2004 May;17(5):547-52 [15001993.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Jun;12(2):160-5 [15354743.001]
  • [Cites] Am J Clin Pathol. 2004 Nov;122(5):721-7 [15491968.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Int J Dev Biol. 1998 May;42(4):561-72 [9694627.001]
  • [Cites] Histopathology. 2005 Jun;46(6):622-34 [15910593.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1025-33 [16006796.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1184-93 [16096408.001]
  • [Cites] Int J Gynecol Pathol. 2006 Apr;25(2):151-4 [16633064.001]
  • [Cites] Semin Diagn Pathol. 2000 Aug;17(3):216-24 [10968707.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Sep;9(3):255-60 [11556754.001]
  • (PMID = 16917000.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Protein c-fli-1
  • [Other-IDs] NLM/ PMC1955051
  •  go-up   go-down


65. Lin Z, Liu M, Li Z, Kim C, Lee E, Kim I: DeltaNp63 protein expression in uterine cervical and endometrial cancers. J Cancer Res Clin Oncol; 2006 Dec;132(12):811-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: DeltaNp63 protein expression was studied in a variety of 127 cases of uterine cervical lesions (20 non-neoplastic cervices, 43 cervical intraepithelial neoplasia [CIN], 54 squamous cell carcinomas (SCCs), 40 adenocarcinomas, and 13 other histologic types) and 30 endometrioid type of endometrial adenocarcinomas by using immunohistochemistry.
  • One SCC cell line (ME-180) and one adenocarcinoma cell line (HeLa) were also included.
  • RESULTS: In uterine cervix, the expression of DeltaNp63 was increased with progression of CIN, and positive in all SCCs, transitional cell carcinomas, and adenoid basal carcinoma, but negative in all adenocarcinomas.
  • Adenosquamous cell carcinoma and mixed neuroendocrine and squamous cell carcinoma were positive in squamous component, but not in adenocarcinoma and neuroendocrine carcinoma components.
  • ME-180 cell line was positive, whereas HeLa cell line was negative.
  • Endometrioid type of endometrial adenocarcinomas showed a positive staining in glandular (26.7%) and squamous component.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. DNA-Binding Proteins / biosynthesis. Endometrial Neoplasms / metabolism. Trans-Activators / biosynthesis. Tumor Suppressor Proteins / biosynthesis. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Antigens, Differentiation / biosynthesis. Cell Line, Tumor. Cervix Uteri / cytology. Cervix Uteri / metabolism. Female. HeLa Cells. Humans. Immunohistochemistry. Transcription Factors

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16804722.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / DNA-Binding Proteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


66. Wang Y, Li Y, Zhang WY, Xia QJ, Li HG, Wang R, Yang L, Sun XF, Zhou ZG: mRNA expression of minichromosome maintenance 2 in colonic adenoma and adenocarcinoma. Eur J Cancer Prev; 2009 Feb;18(1):40-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] mRNA expression of minichromosome maintenance 2 in colonic adenoma and adenocarcinoma.
  • Here, we aimed to evaluate the possible value of a proliferation marker, minichromosome maintenance 2 (MCM2), in the early diagnosis of colorectal cancer, by analyzing the difference in MCM2 expression among normal mucosa, adenoma, and adenocarcinoma, and investigating the relationship of MCM2 expression in adenomas with clinicopathologic variables.
  • Using immunohistochemistry and real-time reverse transcription-PCR, we observed that the expression of MCM2 protein was present on basal third to half of colonic crypts in normal mucosa, whereas throughout the epithelium in adenomas and adenocarcinomas, the expression of MCM2 mRNA in adenocarcinomas was significantly higher than in adenomas (P=0.001), whereas the difference between adenoma and normal mucosa was not significant (P=0.184); we also found that the expression of MCM2 mRNA tended to be increased in the adenomas with high-grade dysplasia, or in older patients, respectively, compared with those with low-grade dysplasia, and younger patients.
  • These results suggested the potential value of MCM2 in early diagnosis of colorectal cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Cell Cycle Proteins / genetics. Colonic Neoplasms / genetics. Nuclear Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077563.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


67. Cuffy M, Abir F, Longo WE: Management of less common tumors of the colon, rectum, and anus. Clin Colorectal Cancer; 2006 Jan;5(5):327-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority of colorectal and anal malignancies are adenocarcinomas and squamous cell cancers, respectively.
  • These tumors often present challenges to clinicians with respect to diagnosis, staging, management, and pathology because of their unfamiliarity.
  • A Medline search using "colon," "rectum,""anus," "lymphoma," "melanoma," "diffuse cavernous hemangioma," "squamous cell carcinoma," "carcinoid," "sarcoma," "leiomyosarcoma," "Kaposi's sarcoma," "Paget's disease," "Bowen's disease," and "basal cell carcinoma" as key words was performed as well as a cross-referencing of the bibliography cited in each work.
  • For some histotypes, such as squamous cell carcinoma and carcinoids of the rectum, treatment depends on location and size of the tumor.
  • For uncommon anal lesions, such as Bowen's disease, Paget's disease, and basal cell carcinoma, wide local excision (WLE) with negative margins is the standard of care.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Colonic Neoplasms / therapy. Hemangioma, Cavernous / therapy. Lymphoma / therapy. Neuroendocrine Tumors / therapy. Rectal Neoplasms / therapy. Sarcoma / therapy

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16512991.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 164
  •  go-up   go-down


68. Khattar NH, Lele SM, Kaetzel CS: Down-regulation of the polymeric immunoglobulin receptor in non-small cell lung carcinoma: correlation with dysregulated expression of the transcription factors USF and AP2. J Biomed Sci; 2005;12(1):65-77
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down-regulation of the polymeric immunoglobulin receptor in non-small cell lung carcinoma: correlation with dysregulated expression of the transcription factors USF and AP2.
  • We have previously shown in cultured tumor cell-lines that basal transcription of the PIGR gene is regulated by the transcription factors USF1, USF2 and AP2.
  • To examine the mechanism by which PIGR expression is down-regulated in lung carcinoma, RNA was microdissected from formalin-fixed, paraffin-embedded lung carcinomas (14 adenocarcinomas and 8 squamous cell carcinomas).
  • PIGR mRNA levels were decreased in adenocarcinomas and squamous cell carcinomas relative to adjacent non-tumor tissue, and were inversely correlated with stage of differentiation.
  • USF1 and USF2 mRNA levels were reduced in adenocarcinomas relative to non-tumor tissue, while AP2-alpha levels were elevated.
  • Multivariate regression analysis demonstrated that reduced USF2 mRNA and increased AP2-alpha mRNA levels were predictive of down-regulated PIGR mRNA expression in the majority of adenocarcinomas and in moderately differentiated squamous cell carcinomas.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. DNA-Binding Proteins / metabolism. Down-Regulation. Lung Neoplasms / metabolism. Receptors, Polymeric Immunoglobulin / metabolism. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15864740.001).
  • [ISSN] 1021-7770
  • [Journal-full-title] Journal of biomedical science
  • [ISO-abbreviation] J. Biomed. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Receptors, Polymeric Immunoglobulin; 0 / Transcription Factor AP-2; 0 / Transcription Factors; 0 / USF1 protein, human; 0 / USF2 protein, human; 0 / Upstream Stimulatory Factors; 63231-63-0 / RNA
  •  go-up   go-down


69. Leinonen T, Pirinen R, Böhm J, Johansson R, Rinne A, Weber E, Kosma VM: Biological and prognostic role of acid cysteine proteinase inhibitor (ACPI, cystatin A) in non-small-cell lung cancer. J Clin Pathol; 2007 May;60(5):515-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological and prognostic role of acid cysteine proteinase inhibitor (ACPI, cystatin A) in non-small-cell lung cancer.
  • AIM: To analyse the expression and prognostic role of ACPI in non-small-cell lung cancer (NSCLC).
  • RESULTS: A normal bronchial epithelium showed positive staining for ACPI in the basal cells, whereas the upper two-thirds of the dysplastic epithelium was ACPI positive.
  • High staining for ACPI was found in 74% (91/123) of squamous-cell carcinomas, whereas 16% (8/49) of adenocarcinomas and 30% of (8/27) large-cell carcinomas showed the high expression of ACPI (p<0.001).
  • Among squamous-cell carcinomas, low expression of ACPI was correlated with poor tumour differentiation (p=0.032).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Cystatins / metabolism. Cysteine Proteinase Inhibitors / metabolism. Lung Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Follow-Up Studies. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Precancerous Conditions / metabolism. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1052-62 [10741734.001]
  • [Cites] Pathol Res Pract. 1980 Dec;170(1-3):172-9 [18788161.001]
  • [Cites] Prostate. 2001 Sep 15;48(4):274-84 [11536307.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3141-9 [12115346.001]
  • [Cites] Cancer Lett. 2002 Dec 10;187(1-2):185-90 [12359367.001]
  • [Cites] Cell Mol Life Sci. 2002 Sep;59(9):1503-12 [12440772.001]
  • [Cites] Prostate. 2003 Mar 1;54(4):290-8 [12539227.001]
  • [Cites] Biochem Soc Symp. 2003;(70):179-99 [14587292.001]
  • [Cites] Acta Chem Scand B. 1975;29(7):772-80 [242173.001]
  • [Cites] Acta Histochem. 1978;63(2):183-92 [107702.001]
  • [Cites] Acta Histochem Suppl. 1980;22:325-9 [6789389.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1983;43(2):121-6 [6137100.001]
  • [Cites] Exp Pathol. 1984;26(2):67-70 [6548973.001]
  • [Cites] J Biochem. 1984 Nov;96(5):1437-42 [6441803.001]
  • [Cites] Anat Anz. 1986;161(3):215-30 [2424340.001]
  • [Cites] Acta Histochem. 1987;82(1):5-18 [3122506.001]
  • [Cites] Biol Chem Hoppe Seyler. 1992 Jul;373(7):595-604 [1515089.001]
  • [Cites] Acta Histochem. 1992;93(1):241-8 [1326833.001]
  • [Cites] Biol Chem Hoppe Seyler. 1995 Feb;376(2):71-80 [7794528.001]
  • [Cites] Int J Cancer. 1995 Jul 4;62(1):1-4 [7541394.001]
  • [Cites] Int J Gynecol Pathol. 1995 Jul;14(3):217-22 [8600072.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1997;254 Suppl 1:S150-3 [9065652.001]
  • [Cites] Clin Exp Metastasis. 1997 Jul;15(4):368-81 [9219725.001]
  • [Cites] Adv Exp Med Biol. 1997;421:259-65 [9330706.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):432-6 [9458085.001]
  • [Cites] Oncol Rep. 1998 Nov-Dec;5(6):1349-61 [9769367.001]
  • [Cites] Neoplasma. 1998;45(5):318-31 [9921922.001]
  • [Cites] Eur J Hum Genet. 2005 Feb;13(2):208-15 [15483648.001]
  • [Cites] Hum Pathol. 2005 Jan;36(1):44-50 [15712181.001]
  • [Cites] J Clin Pathol. 2001 May;54(5):391-5 [11328840.001]
  • (PMID = 16790691.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cystatins; 0 / Cysteine Proteinase Inhibitors
  • [Other-IDs] NLM/ PMC1994551
  •  go-up   go-down


70. Hasumura M, Imai T, Takizawa T, Ueda M, Onose J, Hirose M: Promotion of thyroid carcinogenesis by para-aminobenzoic acid in rats initiated with N-bis(2-hydroxypropyl)nitrosamine. Toxicol Sci; 2005 Jul;86(1):61-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • From 1 week after DHPN initiation, rats in groups 2, 3, 4, and 6 were fed basal diet containing 0.25%, 0.5%, 1.0%, and 1.0% PABA, respectively, for 40 weeks.
  • Rats in groups 1 and 5 received basal diet alone throughout the experiment.
  • The final incidence of thyroid follicular cell adenomas and adenocarcinomas was significantly (p < 0.05 or 0.01) increased in groups 3 and 4 as compared to group 1.
  • In experiment 2, animals in group 1 were fed basal diet alone, while groups 2 and 3 were given 0.5% and 1.0% PABA in the diet, respectively, for 2 weeks.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. 4-AMINOBENZOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15843508.001).
  • [ISSN] 1096-6080
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Nitrosamines; 0 / Thyroid Hormones; 53609-64-6 / diisopropanolnitrosamine; TL2TJE8QTX / 4-Aminobenzoic Acid
  •  go-up   go-down


71. de Ostrovich KK, Lambertz I, Colby JK, Tian J, Rundhaug JE, Johnston D, Conti CJ, DiGiovanni J, Fuchs-Young R: Paracrine overexpression of insulin-like growth factor-1 enhances mammary tumorigenesis in vivo. Am J Pathol; 2008 Sep;173(3):824-34
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To study the role of IGF-1 in mammary tumorigenesis in vivo, we used transgenic mice in which overexpression of IGF-1 is under the control of the bovine keratin 5 (BK5) promoter and is directed to either the myoepithelial or basal cells in a variety of organs, including the mammary gland.
  • The mammary tumors were moderately differentiated adenocarcinomas that expressed functional, nuclear estrogen receptor at both the protein and mRNA levels.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2003 May 15;63(10):2425-33 [12750262.001]
  • [Cites] Endocr Relat Cancer. 2001 Sep;8(3):197-209 [11566611.001]
  • [Cites] Mol Endocrinol. 1989 Mar;3(3):509-17 [2747657.001]
  • [Cites] J Biol Chem. 1990 Dec 5;265(34):21172-8 [2174437.001]
  • [Cites] Carcinogenesis. 1990 Dec;11(12):2245-51 [2265476.001]
  • [Cites] Lancet. 1992 Jan 4;339(8784):1-15 [1345950.001]
  • [Cites] Mol Endocrinol. 1993 Jun;7(6):743-52 [7689695.001]
  • [Cites] Mol Endocrinol. 1994 Apr;8(4):510-7 [8052269.001]
  • [Cites] Differentiation. 1994 Nov;58(1):53-64 [7532601.001]
  • [Cites] Science. 1995 Dec 1;270(5241):1491-4 [7491495.001]
  • [Cites] Endocrinology. 1996 Jan;137(1):321-30 [8536631.001]
  • [Cites] Mutat Res. 1995 Dec;333(1-2):29-35 [8538632.001]
  • [Cites] Environ Health Perspect. 1996 Sep;104(9):938-67 [8899375.001]
  • [Cites] J Biol Chem. 1997 Jan 3;272(1):154-61 [8995241.001]
  • [Cites] J Endocrinol. 1997 Jan;152(1):39-47 [9014838.001]
  • [Cites] Carcinogenesis. 1997 Mar;18(3):459-64 [9067542.001]
  • [Cites] Carcinogenesis. 1997 Mar;18(3):553-9 [9067556.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3079-83 [9242428.001]
  • [Cites] J Androl. 1997 Nov-Dec;18(6):602-11 [9432133.001]
  • [Cites] Lancet. 1998 May 9;351(9113):1393-6 [9593409.001]
  • [Cites] Endocrine. 1998 Jun;8(3):251-9 [9741830.001]
  • [Cites] Mol Endocrinol. 1999 May;13(5):787-96 [10319328.001]
  • [Cites] Am J Pathol. 2005 Feb;166(2):575-84 [15681840.001]
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):9817-24 [11139588.001]
  • [Cites] Microsc Res Tech. 2001 Jan 15;52(2):155-62 [11169863.001]
  • [Cites] Mol Pathol. 2001 Oct;54(5):311-6 [11577173.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):968-88 [10713680.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3455-60 [10737798.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1561-70 [10749124.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Jan;5(1):7-17 [10791764.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Jan;5(1):19-30 [10791765.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Jan;5(1):31-42 [10791766.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Jan;5(1):95-105 [10791772.001]
  • [Cites] Eur J Cancer. 2000 Jun;36(10):1224-8 [10882860.001]
  • [Cites] Neoplasia. 2002 May-Jun;4(3):204-17 [11988840.001]
  • [Cites] Endocrinology. 2002 Jul;143(7):2673-9 [12072401.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):705-12 [12163322.001]
  • [Cites] Breast Cancer Res Treat. 2002 Jun;74(3):199-211 [12206512.001]
  • [Cites] Tumour Biol. 2002 May-Jun;23(3):130-8 [12218293.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):47645-52 [12364325.001]
  • [Cites] Breast Cancer Res. 2002;4(6):231-9 [12473169.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3781-7 [15867374.001]
  • [Cites] Mol Carcinog. 2005 Oct;44(2):137-45 [16086373.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):273-8 [16728563.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):583-92 [16728584.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):584-94 [17050554.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):763-8 [17416768.001]
  • [Cites] Pituitary. 2007;10(2):129-33 [17487588.001]
  • [Cites] Nat Rev Cancer. 2007 Sep;7(9):659-72 [17721431.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10879-88 [18006833.001]
  • [Cites] Exp Cell Res. 2002 Feb 1;273(1):107-17 [11795951.001]
  • [Cites] Oncology. 1999 Nov;57(4):330-40 [10575321.001]
  • [Cites] Mol Carcinog. 2000 Jan;27(1):10-7 [10642432.001]
  • [Cites] Oncogene. 2000 Feb 17;19(7):889-98 [10702797.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):21695-702 [10777488.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1472-89 [10995803.001]
  • [Cites] J Biol Chem. 2000 Nov 17;275(46):35893-901 [10967123.001]
  • [Cites] J Endocrinol. 2000 Aug;166(2):329-38 [10927622.001]
  • [Cites] J Nutr. 1979 May;109(5):925-6 [438904.001]
  • (PMID = 18688034.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / R01 CA037111; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / CA 104114; United States / NCI NIH HHS / CA / R01 CA104114; United States / NIEHS NIH HHS / ES / P30 ES007784; United States / NCI NIH HHS / CA / CA37111; United States / NIEHS NIH HHS / ES / ES07784
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-5; 0 / Keratin-8; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 136601-57-5 / Cyclin D1; 67763-96-6 / Insulin-Like Growth Factor I
  • [Other-IDs] NLM/ PMC2527085
  •  go-up   go-down


72. Kuroiwa Y, Nishikawa A, Kitamura Y, Kanki K, Ishii Y, Umemura T, Hirose M: Protective effects of benzyl isothiocyanate and sulforaphane but not resveratrol against initiation of pancreatic carcinogenesis in hamsters. Cancer Lett; 2006 Sep 28;241(2):275-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With post-initiation exposure, the groups were changed from basal diet 1 week after the last BOP injection, and then fed each chemical for 14 weeks.
  • The multiplicities of combined pancreatic lesions including atypical hyperplasias and adenocarcinomas were significantly decreased by BITC and SFN given in the initiation but not the post-initiation stage.
  • [MeSH-minor] Adenocarcinoma / chemically induced. Adenocarcinoma / prevention & control. Animals. Antineoplastic Agents, Phytogenic / administration & dosage. Carcinogenicity Tests. Carcinogens / toxicity. Cell Transformation, Neoplastic. Cricetinae. Cyclooxygenase 2 / metabolism. Diet. Injections, Subcutaneous. Male. Membrane Proteins / metabolism. Mesocricetus. Nitrosamines / toxicity

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. RESVERATROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16386831.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Carcinogens; 0 / Isothiocyanates; 0 / Membrane Proteins; 0 / Nitrosamines; 0 / Stilbenes; 0 / Thiocyanates; 4478-93-7 / sulforafan; 60599-38-4 / nitrosobis(2-oxopropyl)amine; 871J6YOR8Q / benzyl isothiocyanate; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; Q369O8926L / resveratrol
  •  go-up   go-down


73. Yuan P, Kadara H, Behrens C, Tang X, Woods D, Solis LM, Huang J, Spinola M, Dong W, Yin G, Fujimoto J, Kim E, Xie Y, Girard L, Moran C, Hong WK, Minna JD, Wistuba II: Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One; 2010 Feb 09;5(2):e9112
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung.
  • BACKGROUND: Non-small cell lung cancer (NSCLC) represents the majority (85%) of lung cancers and is comprised mainly of adenocarcinomas and squamous cell carcinomas (SCCs).
  • The sequential pathogenesis of lung adenocarcinomas and SCCs occurs through dissimilar phases as the former tumors typically arise in the lung periphery whereas the latter normally arise near the central airway.
  • METHODOLOGY/PRINCIPAL FINDINGS: We assessed the expression of SOX2, an embryonic stem cell transcriptional factor that also plays important roles in the proliferation of basal tracheal cells and whose expression is restricted to the main and central airways and bronchioles of the developing and adult mouse lung, in NSCLC by various methodologies.
  • Here, we found that SOX2 mRNA levels, from various published datasets, were significantly elevated in lung SCCs compared to adenocarcinomas (all p<0.001).
  • Moreover, a previously characterized OCT4/SOX2/NANOG signature effectively separated lung SCCs from adenocarcinomas in two independent publicly available datasets which correlated with increased SOX2 mRNA in SCCs.
  • Moreover, SOX2 protein expression was greatly higher in lung SCCs compared to adenocarcinomas following analyses in two independent large TMA sets (TMA set I, n = 287; TMA set II, n = 511 both p<0.001).
  • Furthermore, amplification of SOX2 DNA was detected in 20% of lung SCCs tested (n = 40) and in none of the adenocarcinomas (n = 17).
  • CONCLUSIONS/SIGNIFICANCE: Our findings highlight a cell-lineage gene expression pattern for the stem cell transcriptional factor SOX2 in the pathogenesis of lung SCCs and suggest a differential activation of stem cell-related pathways between squamous cell carcinomas and adenocarcinomas of the lung.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Nat Genet. 2009 Nov;41(11):1238-42 [19801978.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]
  • [Cites] Cancer Res. 1996 May 1;56(9):2224-8 [8616876.001]
  • [Cites] Development. 1997 Dec;124(23):4867-78 [9428423.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11891-6 [9751761.001]
  • [Cites] Genes Dev. 1998 Oct 15;12(20):3156-61 [9784490.001]
  • [Cites] Cell. 2005 Sep 23;122(6):947-56 [16153702.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Nov;6(11):872-84 [16227977.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):353-7 [16273092.001]
  • [Cites] Annu Rev Pathol. 2006;1:331-48 [18039118.001]
  • [Cites] Dev Biol. 2008 May 1;317(1):296-309 [18374910.001]
  • [Cites] Oncogene. 2008 Jun 5;27(25):3635-40 [18212743.001]
  • [Cites] N Engl J Med. 2008 Sep 25;359(13):1367-80 [18815398.001]
  • [Cites] Clin Cancer Res. 2008 Oct 1;14(19):6014-22 [18829480.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Aug;1(3):192-200 [19138956.001]
  • [Cites] Development. 2009 Jun;136(11):1899-907 [19403656.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • (PMID = 20161759.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / CA-16672; United States / NCI NIH HHS / CA / P50CA70907
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / NANOG protein, human; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human; 0 / SOX2 protein, human; 0 / SOXB1 Transcription Factors
  • [Other-IDs] NLM/ PMC2817751
  •  go-up   go-down


74. Wang XD, Leow CC, Zha J, Tang Z, Modrusan Z, Radtke F, Aguet M, de Sauvage FJ, Gao WQ: Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation. Dev Biol; 2006 Feb 1;290(1):66-80
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation.
  • Notch pathway is crucial for stem/progenitor cell maintenance, growth and differentiation in a variety of tissues.
  • Using a transgenic cell ablation approach, we found in our previous study that cells expressing Notch1 are crucial for prostate early development and re-growth.
  • Here, we further define the role of Notch signaling in regulating prostatic epithelial cell growth and differentiation using biochemical and genetic approaches in ex vivo or in vivo systems.
  • Treatment of developing prostate grown in culture with inhibitors of gamma-secretase/presenilin, which is required for Notch cleavage and activation, caused a robust increase in proliferation of epithelial cells co-expressing cytokeratin 8 and 14, lack of luminal/basal layer segregation and dramatically reduced branching morphogenesis.
  • Cells within these lesions co-expressed both luminal and basal cell markers, a feature of prostatic epithelial cells in predifferentiation developmental stages.
  • Furthermore, expression of Notch1 and its effector Hey-1 gene in human prostate adenocarcinomas were found significantly down-regulated compared to normal control tissues.
  • Taken together, these data suggest that Notch signaling is critical for normal cell proliferation and differentiation in the prostate, and deregulation of this pathway may facilitate prostatic tumorigenesis.
  • [MeSH-major] Cell Differentiation. Cell Proliferation. Epithelial Cells / metabolism. Prostate / metabolism. Receptor, Notch1 / metabolism. Stem Cells / metabolism
  • [MeSH-minor] Amyloid Precursor Protein Secretases. Animals. Animals, Newborn. Aspartic Acid Endopeptidases. Basic Helix-Loop-Helix Transcription Factors / metabolism. Cell Cycle Proteins / metabolism. Cell Transformation, Neoplastic. Cells, Cultured. Down-Regulation. Endopeptidases / metabolism. Humans. Keratins / metabolism. Male. Mice. Mice, Knockout. Morphogenesis. Oligonucleotide Array Sequence Analysis. Protease Inhibitors / pharmacology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16360140.001).
  • [ISSN] 0012-1606
  • [Journal-full-title] Developmental biology
  • [ISO-abbreviation] Dev. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Cell Cycle Proteins; 0 / HEY1 protein, human; 0 / Protease Inhibitors; 0 / Receptor, Notch1; 68238-35-7 / Keratins; EC 3.4.- / Amyloid Precursor Protein Secretases; EC 3.4.- / Endopeptidases; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.46 / BACE1 protein, human; EC 3.4.23.46 / Bace1 protein, mouse
  •  go-up   go-down


75. Tanaka T, de Azevedo MB, Durán N, Alderete JB, Epifano F, Genovese S, Tanaka M, Tanaka T, Curini M: Colorectal cancer chemoprevention by 2 beta-cyclodextrin inclusion compounds of auraptene and 4'-geranyloxyferulic acid. Int J Cancer; 2010 Feb 15;126(4):830-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They were then given a basal diet containing 2 dose levels (100 and 500 ppm) of GOFA/beta-CD or AUR/beta-CD for 15 weeks.
  • At Week 18, the development of colonic adenocarcinoma was significantly inhibited by feeding with GOFA/beta-CD at dose levels of 100 ppm (63% reduction in multiplicity, p < 0.05) and 500 ppm (83% reduction in the multiplicity, p < 0.001), when compared with the AOM/DSS group (multiplicity: 3.36 +/- 3.34).
  • In addition, feeding with 100 and 500 ppm (p < 0.01) of AUR/beta-CD suppressed the development of colonic adenocarcinomas.
  • The dietary administration with GOFA/beta-CD and AUR/beta-CD inhibited colonic inflammation and also modulated proliferation, apoptosis and the expression of several proinflammatory cytokines, such as nuclear factor-kappaB, tumor necrosis factor-alpha, Stat3, NF-E2-related factor 2, interleukin (IL)-6 and IL-1beta, which were induced in the adenocarcinomas.
  • [MeSH-minor] Animals. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Diterpenes / therapeutic use. Humans. Immunohistochemistry. Incidence. Inflammation / drug therapy. Inflammation / etiology. Inflammation / pathology. Inflammatory Bowel Diseases / complications. Inhibitor of Apoptosis Proteins. Interleukin-1beta / metabolism. Interleukin-6 / metabolism. Male. Mice. Mice, Inbred ICR. Microtubule-Associated Proteins / metabolism. NF-kappa B / metabolism. Proliferating Cell Nuclear Antigen / metabolism. Propionates / therapeutic use. Repressor Proteins. Tumor Necrosis Factor-alpha / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688830.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 3-(4'-geranyloxy-3'-methoxyphenyl)-2-trans-propenoic acid; 0 / Birc5 protein, mouse; 0 / Coumarins; 0 / Diterpenes; 0 / Inhibitor of Apoptosis Proteins; 0 / Interleukin-1beta; 0 / Interleukin-6; 0 / Microtubule-Associated Proteins; 0 / NF-kappa B; 0 / Proliferating Cell Nuclear Antigen; 0 / Propionates; 0 / Repressor Proteins; 0 / Tumor Necrosis Factor-alpha; 0 / beta-Cyclodextrins; 495-02-3 / aurapten
  •  go-up   go-down


76. Forest V, Campos L, Péoc'h M, Guyotat D, Vergnon JM: [Development of an experimental model for the study of the effects of cryotherapy on lung tumours]. Pathol Biol (Paris); 2005 May;53(4):199-203
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenocarcinomas are today the most frequent lung cancers.
  • MATERIALS AND METHODS: A xenograft system was used: cells from the A549 cell line were injected subcutaneously into SCID mice.
  • The histological study showed that these tumours faithfully reproduced the morphological features of adenocarcinoma, and developed an intratumoral neovascularization.
  • RESULTS: The basal expression of cleaved caspase-3 in untreated tumours (23%) increased after cryotherapy.
  • [MeSH-major] Adenocarcinoma / therapy. Cryotherapy. Lung Neoplasms / therapy. Neoadjuvant Therapy. Neoplasms, Experimental / therapy
  • [MeSH-minor] Animals. Cell Line, Tumor / transplantation. Humans. Male. Mice. Mice, SCID. Neoplasm Transplantation. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15850952.001).
  • [ISSN] 0369-8114
  • [Journal-full-title] Pathologie-biologie
  • [ISO-abbreviation] Pathol. Biol.
  • [Language] fre
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  •  go-up   go-down


77. Lisovsky M, Ogawa F, Dresser K, Woda B, Lauwers GY: Loss of cell polarity protein Lgl2 in foveolar-type gastric dysplasia: correlation with expression of the apical marker aPKC-zeta. Virchows Arch; 2010 Dec;457(6):635-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of cell polarity protein Lgl2 in foveolar-type gastric dysplasia: correlation with expression of the apical marker aPKC-zeta.
  • Since atypical protein kinase C (aPKC) is a partner of Lgl2 in the control of apical-basal polarity we also investigated whether aPKC-zeta can compliment Lgl2 as a marker of dysplasia.
  • Routinely processed specimens included 64 normal mucosa, 35 reactive gastropathies, 31 chronic gastritides, 65 gastric dysplasias (25 foveolar; 40 adenomatous), and 34 gastric adenocarcinomas.
  • Apical aPKC-zeta staining was lost in 97% of gastric adenocarcinomas.
  • Our data suggest a role of Lgl2 immunohistochemistry as an adjunct in the diagnosis of foveolar-type gastric dysplasia. aPKC-zeta had moderate sensitivity as a marker of gastric dysplasia and additional studies are needed to establish its role in the diagnosis of dysplasia.
  • [MeSH-major] Cell Polarity / physiology. Cytoskeletal Proteins / metabolism. Precancerous Conditions / metabolism. Protein Kinase C / metabolism. Stomach Diseases / metabolism
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers / metabolism. Diagnosis, Differential. Gastritis / diagnosis. Gastritis / metabolism. Gastritis / pathology. Humans. Intestinal Mucosa / metabolism. Sensitivity and Specificity. Stomach Neoplasms / diagnosis. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20941506.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cytoskeletal Proteins; 0 / Hugl-2 protein, human; EC 2.7.11.1 / protein kinase C zeta; EC 2.7.11.13 / Protein Kinase C
  •  go-up   go-down


78. Delektorskaya VV, Golovkov DA, Kushlinskii NE: Clinical significance of levels of molecular biological markers in zones of invasive front-line of colorectal cancer. Bull Exp Biol Med; 2008 Nov;146(5):616-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The role of expression of markers (beta-catenin, matrix metalloproteinase 9, collagen IV, and laminin) in primary colorectal adenocarcinomas and their metastases in the liver and lymph nodes of patients with colorectal cancer was studied.
  • High level of matrix metalloproteinase 9 expression in zones of invasive growth of colorectal cancer was associated with high accumulation of beta-catenin in cancer cell nuclei in the peripheral zones of 30% studied tumors.
  • The presence of nuclear beta-catenin and high content of matrix metalloproteinase 9 in the tumor were associated with abnormal accumulation of laminin in the cytoplasm and with the absence of basal membranes containing collagen IV.
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / metabolism. Biomarkers / metabolism. Collagen Type IV / metabolism. Humans. Immunohistochemistry. In Vitro Techniques. Laminin / metabolism. Liver Neoplasms / enzymology. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lymphatic Metastasis / pathology. Matrix Metalloproteinase 9 / metabolism. beta Catenin / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526105.001).
  • [ISSN] 0007-4888
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Collagen Type IV; 0 / Laminin; 0 / beta Catenin; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


79. Macias E, Miliani de Marval PL, Senderowicz A, Cullen J, Rodriguez-Puebla ML: Expression of CDK4 or CDK2 in mouse oral cavity is retained in adult pituitary with distinct effects on tumorigenesis. Cancer Res; 2008 Jan 1;68(1):162-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The keratin 5 (K5) promoter drives transgenic expression to the basal cell layer of stratified epithelia.
  • Furthermore, retention of CDK4 in these TA-like pituitary cells synergizes with loss of p27(Kip1) to induce pituitary adenocarcinomas.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18172308.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA090864; United States / NCI NIH HHS / CA / R01 CA116328; United States / NCI NIH HHS / CA / CA116328; United States / NCI NIH HHS / CA / CA90864
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cdkn1b protein, mouse; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 2.7.11.22 / Cyclin-Dependent Kinase 2; EC 2.7.11.22 / Cyclin-Dependent Kinase 4
  •  go-up   go-down


80. Janković-Velicković L, Katić V, Ignjatović I: [Morphological markers of secretory activity in prostatic adenocarcinoma]. Vojnosanit Pregl; 2007 Sep;64(9):617-22
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphological markers of secretory activity in prostatic adenocarcinoma].
  • BACKGROUND/AIM: The vast majority of prostatic tumors developing in adult males are adenocarcinomas (ACP).
  • Histological diagnosis of prostate cancer relies on the infiltrative growth pattern, presence of macronucleoli, and absence of basal cell layer.
  • [MeSH-major] Adenocarcinoma / secretion. Prostatic Neoplasms / secretion

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17969817.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


81. Garcia MT, Acar BC, Jorda M, Gomez-Fernandez C, Ganjei-Azar P: Use of p63 for distinction of glandular versus squamous lesions in cervicovaginal specimens. Cancer; 2007 Feb 25;111(1):54-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Squamous and atypical glandular cell lesions may show similar cytomorphologic features.
  • The aim of this study was to evaluate the use of p63 as a marker of basal and/or squamous cell derivation in this differential diagnosis.
  • METHODS: Of 59,257 liquid-based cervicovaginal specimens collected over a 3-year period, 149 were diagnosed as atypical glandular cells of uncertain significance (AGUS) or adenocarcinoma and had histological follow-up.
  • Ten cases (8AGUS and 2 adenocarcinomas) were proven to be high-grade dysplasia on cervical biopsies and the remaining cases represented glandular pathology.
  • In addition, the authors stained 25 control cases (10 adenocarcinomas, 10 HSIL, and 5 negative cervicovaginal specimens).
  • Nuclei of isolated HSIL cells and basal cells from atrophic smears were also positive for p63.
  • This antibody is not expressed in AGUS, adenocarcinoma, or normal glandular cells. p63 stains basal cells and may be a diagnostic pitfall in atrophic cervicovaginal specimens.
  • [MeSH-major] Membrane Proteins / metabolism. Neoplasms, Glandular and Epithelial / diagnosis. Neoplasms, Squamous Cell / diagnosis. Uterine Cervical Neoplasms / diagnosis. Vaginal Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers, Tumor / immunology. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry / methods


82. Bozdogan O, Atasoy P, Bozdogan N, Erekul S, Batislam E, Yilmaz E, Başar MM: BAG-1 expression in hyperplastic and neoplastic prostate tissue: is there any relationship with BCL-related proteins and androgen receptor status? Tumori; 2005 Nov-Dec;91(6):539-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Twenty-eight prostatic adenocarcinomas and 16 prostate hyperplasias were included in this retrospective study.
  • BAG-1 showed the same specific basal cell localization as BCL-2 in hyperplastic and normal glands.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. DNA-Binding Proteins / analysis. Prostatic Hyperplasia / metabolism. Prostatic Neoplasms / chemistry. Receptors, Androgen / analysis. Transcription Factors / analysis

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16457154.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / BCL2-associated athanogene 1 protein; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Receptors, Androgen; 0 / Transcription Factors
  •  go-up   go-down


83. Brennan D, Mahoney MG: Increased expression of Dsg2 in malignant skin carcinomas: A tissue-microarray based study. Cell Adh Migr; 2009 Apr-Jun;3(2):148-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Desmoglein 2 (Dsg2), a transmembrane cadherin of the desmosomal cell-cell adhesion structure, is downregulated with epithelial differentiation.
  • We recently demonstrated that overexpression of Dsg2 in epidermal keratinocytes deregulates multiple signaling pathways associated with increased growth rate, anchorage-independent cell survival, and the development of skin tumors.
  • Using these antibodies in immunostaining of tissue microarrays, we show a dramatic upregulation of Dsg2 expression in certain human epithelial malignancies including basal cell carcinomas (BCC; n = 12), squamous cell carcinomas (SCC; n = 57), carcinomas of sebaceous and sweat glands (n = 12), and adenocarcinomas (n = 3).

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2007 Sep;127(9):2191-206 [17495963.001]
  • [Cites] Br J Cancer. 2007 Jun 18;96(12):1783-7 [17519903.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):7003-11 [18056176.001]
  • [Cites] Mod Pathol. 2008 Mar;21(3):271-81 [18084253.001]
  • [Cites] Adv Exp Med Biol. 2008;624:283-95 [18348464.001]
  • [Cites] Adv Anat Pathol. 2008 Jul;15(4):234-40 [18580099.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):65-73 [10638968.001]
  • [Cites] Ann Surg Oncol. 2000 Apr;7(3):204-9 [10791851.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3397-403 [10910046.001]
  • [Cites] Arch Pathol Lab Med. 2000 Aug;124(8):1147-51 [10923074.001]
  • [Cites] Pathol Res Pract. 2001;197(2):85-91 [11261822.001]
  • [Cites] Hybrid Hybridomics. 2002 Feb;21(1):37-44 [11991815.001]
  • [Cites] Exp Dermatol. 2002 Apr;11(2):115-25 [11994138.001]
  • [Cites] J Cutan Pathol. 2003 Nov;30(10):621-30 [14744087.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1242-52 [15051772.001]
  • [Cites] Differentiation. 1996 May;60(2):99-108 [8641550.001]
  • [Cites] J Cell Sci. 1996 May;109 ( Pt 5):1143-54 [8743961.001]
  • [Cites] Acta Derm Venereol. 1996 Nov;76(6):417-20 [8982400.001]
  • [Cites] Exp Cell Res. 1998 Feb 25;239(1):50-9 [9511724.001]
  • [Cites] Br J Cancer. 1998 Apr;77(8):1275-9 [9579833.001]
  • [Cites] J Pathol. 1998 Apr;184(4):369-81 [9664902.001]
  • [Cites] Biol Reprod. 1998 Aug;59(2):388-94 [9687312.001]
  • [Cites] Differentiation. 2004 Oct;72(8):434-49 [15606502.001]
  • [Cites] Int J Cancer. 2005 May 1;114(5):779-90 [15609307.001]
  • [Cites] Anticancer Res. 2005 Jan-Feb;25(1A):183-91 [15816537.001]
  • [Cites] J Pathol. 2005 Oct;207(2):199-206 [16025435.001]
  • [Cites] Exp Dermatol. 2006 Feb;15(2):101-9 [16433681.001]
  • [Cites] J Cell Sci. 2007 Mar 1;120(Pt 5):758-71 [17284515.001]
  • [Cites] Int Rev Cytol. 2007;264:65-163 [17964922.001]
  • (PMID = 19458482.001).
  • [ISSN] 1933-6926
  • [Journal-full-title] Cell adhesion & migration
  • [ISO-abbreviation] Cell Adh Migr
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / R21 AR055251; United States / NIAMS NIH HHS / AR / AR055251
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Desmoglein 2
  • [Other-IDs] NLM/ PMC2679873
  •  go-up   go-down


84. Trevino JG, Gray MJ, Nawrocki ST, Summy JM, Lesslie DP, Evans DB, Sawyer TK, Shakespeare WC, Watowich SS, Chiao PJ, McConkey DJ, Gallick GE: Src activation of Stat3 is an independent requirement from NF-kappaB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells. Angiogenesis; 2006;9(2):101-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Src activation of Stat3 is an independent requirement from NF-kappaB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells.
  • Human pancreatic tumors often overexpress the angiogenesis-promoting factor Interleukin 8 (IL-8), in part due to overexpression of NF-kappaB, a frequent occurrence in pancreatic adenocarcinoma.
  • Pharmacologic inhibition of NF-kappaB activity significantly reduced basal IL-8 expression and tumor necrosis factor-induced IL-8 expression (P < 0.05 for both), yet NF-kappaB activity was not dependent on Src.
  • We therefore suggest that Src activation, through phosphorylation of STAT3, and NF-kappaB are all required for expression of IL-8 a critical angiogenic-promoting factor in pancreatic adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Interleukin-8 / metabolism. NF-kappa B / metabolism. Pancreatic Neoplasms / metabolism. Proto-Oncogene Proteins pp60(c-src) / metabolism. STAT3 Transcription Factor / metabolism
  • [MeSH-minor] Cell Line, Tumor. Genes, Reporter. Humans. Immunohistochemistry. Luciferases / metabolism. Microscopy, Confocal. Phosphorylation. RNA, Small Interfering / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16871430.001).
  • [ISSN] 0969-6970
  • [Journal-full-title] Angiogenesis
  • [ISO-abbreviation] Angiogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2R01-1 CA65527; United States / NCI NIH HHS / CA / T32 CA 09599; United States / NCI NIH HHS / CA / U54 CA 090810-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Interleukin-8; 0 / NF-kappa B; 0 / RNA, Small Interfering; 0 / STAT3 Transcription Factor; EC 1.13.12.- / Luciferases; EC 2.7.10.2 / Proto-Oncogene Proteins pp60(c-src)
  •  go-up   go-down


85. Birkenkamp-Demtröder K, Wagner L, Brandt Sørensen F, Bording Astrup L, Gartner W, Scherübl H, Heine B, Christiansen P, Ørntoft TF: Secretagogin is a novel marker for neuroendocrine differentiation. Neuroendocrinology; 2005;82(2):121-38
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our previous microarray-based studies identified secretagogin to be highly expressed in normal colon mucosa compared to basal expression in colon adenocarcinomas.
  • The aim of this study was to analyze the differential expression of secretagogin in normal mucosa, adenocarcinomas, and neuroendocrine tumors.
  • Combined immunohistochemical analysis of secretagogin and FK506-binding protein 65, a protein de novo synthesized in adenocarcinomas, distinguished well-differentiated carcinoids, adenocarcinoids and undifferentiated carcinomas.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Blotting, Western. Carcinoid Tumor / metabolism. Carcinoid Tumor / pathology. Cell Differentiation / physiology. Chromogranin A. Chromogranins / metabolism. Female. Humans. Immunohistochemistry. Lung Neoplasms / secondary. Male. Microscopy, Fluorescence. Middle Aged. Neoplasm Metastasis. Oligonucleotide Array Sequence Analysis. Peptidylprolyl Isomerase / metabolism. Phosphopyruvate Hydratase / metabolism. Secretagogins. Synaptophysin / metabolism. Tacrolimus Binding Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16449819.001).
  • [ISSN] 0028-3835
  • [Journal-full-title] Neuroendocrinology
  • [ISO-abbreviation] Neuroendocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / Chromogranin A; 0 / Chromogranins; 0 / SCGN protein, human; 0 / Secretagogins; 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase; EC 5.2.1.- / Tacrolimus Binding Proteins; EC 5.2.1.8 / FKBP10 protein, human; EC 5.2.1.8 / Peptidylprolyl Isomerase
  •  go-up   go-down


86. Devaney KO, Boschman CR, Willard SC, Ferlito A, Rinaldo A: Tumours of the external ear and temporal bone. Lancet Oncol; 2005 Jun;6(6):411-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The external ear can be the site of development of squamous carcinomas and basal-cell carcinomas; the middle ear and inner ear can host metastatic deposits, and primary squamous carcinomas and adenocarcinomas.
  • [MeSH-major] Ear Neoplasms / diagnosis. Ear Neoplasms / therapy. Ear, External. Skull Neoplasms / diagnosis. Skull Neoplasms / therapy. Temporal Bone

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15925819.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 76
  •  go-up   go-down


87. Leite KR, Srougi M, Sanudo A, Dall'oglio MF, Nesrallah A, Antunes AA, Cury J, Camara-Lopes LH: The use of immunohistochemistry for diagnosis of prostate cancer. Int Braz J Urol; 2010 Sep-Oct;36(5):583-90
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of immunohistochemistry for diagnosis of prostate cancer.
  • The use of antibodies to mark basal cells is currently a common practice, in order to avoid rebiopsies.
  • There has been no reported study that has reviewed characteristics of radical prostatectomies (RPs) when immunohistochemistry (IHC) was necessary for definitive diagnosis.
  • The results of surgical specimens of 27 patients treated by RP after the diagnosis of prostate cancer (PC) was made using IHC (Group 1) were compared with 1040 patients where IHC was not necessary (Group 2).
  • In Group 1, two (7.4%) adenocarcinomas were insignificant versus 29 (2.9%) for Group 2.
  • CONCLUSION: The use of IHC did not lead to diagnosis of insignificant tumors as illustrated by absence of differences in pathological stage or positive surgical margins in men submitted to RP.
  • [MeSH-major] Adenocarcinoma / pathology. Prostate / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy. Cell Proliferation. Humans. Immunohistochemistry / methods. Male. Middle Aged

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21044375.001).
  • [ISSN] 1677-6119
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


88. Triplett AA, Montagna C, Wagner KU: A mammary-specific, long-range deletion on mouse chromosome 11 accelerates Brca1-associated mammary tumorigenesis. Neoplasia; 2008 Dec;10(12):1325-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On the histopathologic level, these tumors were either adenocarcinomas or benign, inflammatory lesions.
  • Like human BRCA1-associated breast cancers, mammary carcinomas in this new mouse model were ERalpha-negative and of basal epithelial origin.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Funct. 1997 Nov;1(4):233-44 [9678900.001]
  • [Cites] Oncogene. 2008 Jan 31;27(6):794-802 [17653086.001]
  • [Cites] Oncogene. 1998 Dec 17;17(24):3169-76 [9872332.001]
  • [Cites] Nat Genet. 1999 May;22(1):37-43 [10319859.001]
  • [Cites] Cancer. 1999 May 15;85(10):2200-5 [10326698.001]
  • [Cites] Breast Cancer Res Treat. 1999 Feb;53(3):217-27 [10369068.001]
  • [Cites] Genes Dev. 1999 Oct 1;13(19):2604-16 [10521404.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3706-12 [10919637.001]
  • [Cites] Oncogene. 2001 Nov 8;20(51):7514-23 [11709723.001]
  • [Cites] Transgenic Res. 2001 Dec;10(6):545-53 [11817542.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2310-8 [11981002.001]
  • [Cites] Oncogene. 2002 Aug 1;21(33):5097-107 [12140760.001]
  • [Cites] J Biol Chem. 2002 Nov 8;277(45):43216-23 [12205095.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2179-87 [12727837.001]
  • [Cites] Oncogene. 2003 May 22;22(21):3288-96 [12761499.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4978-83 [12941823.001]
  • [Cites] J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5 [14519755.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(12):5510-20 [15169911.001]
  • [Cites] Nat Rev Cancer. 2004 Sep;4(9):665-76 [15343273.001]
  • [Cites] Lancet. 1994 Sep 10;344(8924):761 [7915813.001]
  • [Cites] N Engl J Med. 1997 May 15;336(20):1401-8 [9145676.001]
  • [Cites] Nucleic Acids Res. 1997 Nov 1;25(21):4323-30 [9336464.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):4987-91 [9371488.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1969-77 [9586917.001]
  • [Cites] Cell Cycle. 2004 Nov;3(11):1451-6 [15492509.001]
  • [Cites] Genesis. 2005 Sep;43(1):1-11 [16106354.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2196-201 [16452162.001]
  • [Cites] Nucleic Acids Res. 2006;34(5):1416-26 [16522651.001]
  • [Cites] Gene Expr Patterns. 2006 Aug;6(6):653-65 [16466971.001]
  • [Cites] Oncogene. 2006 Sep 25;25(43):5885-97 [16998503.001]
  • [Cites] J Pathol. 2007 Mar;211(4):389-98 [17212342.001]
  • [Cites] Mol Endocrinol. 2007 Aug;21(8):1877-92 [17519353.001]
  • [Cites] Oncogene. 2007 Nov 8;26(51):7204-12 [17496925.001]
  • [Cites] Genetics. 1998 Nov;150(3):1155-68 [9799267.001]
  • (PMID = 19048111.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / BRCA1 Protein; 0 / Cdkn1a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Estrogen Receptor alpha; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2586683
  •  go-up   go-down


89. Bister V, Skoog T, Virolainen S, Kiviluoto T, Puolakkainen P, Saarialho-Kere U: Increased expression of matrix metalloproteinases-21 and -26 and TIMP-4 in pancreatic adenocarcinoma. Mod Pathol; 2007 Nov;20(11):1128-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of matrix metalloproteinases-21 and -26 and TIMP-4 in pancreatic adenocarcinoma.
  • Pancreatic adenocarcinoma is known for early aggressive local invasion, high metastatic potential, and a low 5-year survival rate.
  • We studied the expression of MMP-21, -26, and tissue inhibitor of matrix metalloproteinases (TIMP)-4 in 50 tissue samples, including 25 adenocarcinomas, seven other malignant pancreatic tumors, and 18 control samples of non-neoplastic pancreatic tissue with immunohistochemistry.
  • The regulation of MMP-21, -26, and TIMP-4 mRNAs by cytokines was studied with RT-PCR in pancreatic cancer cell lines PANC-1, BxPC-3, and AsPC-1.
  • All cultured cancer cell lines expressed MMP-21 basally at low levels, and presence of the protein was confirmed immunohistochemically in cultured cells.
  • Basal TIMP-4 expression was lowest in the poorly differentiated cancer cell line PANC-1 compared to better-differentiated BxPC-3 and AsPC-1 cells.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / analysis. Matrix Metalloproteinases / biosynthesis. Matrix Metalloproteinases, Secreted / biosynthesis. Pancreatic Neoplasms / metabolism. Tissue Inhibitor of Metalloproteinases / biosynthesis
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis / physiopathology. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17873896.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinases; 0 / tissue inhibitor of metalloproteinase-4; EC 3.4.24.- / MMP21 protein, human; EC 3.4.24.- / Matrix Metalloproteinases; EC 3.4.24.- / Matrix Metalloproteinases, Secreted
  •  go-up   go-down


90. Puebla-Mora AG, Heras A, Cano-Valdez AM, Domínguez-Malagón H: Human telomerase and alpha-methylacyl-coenzyme A racemase in prostatic carcinoma. A comparative immunohistochemical study. Ann Diagn Pathol; 2006 Aug;10(4):205-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human telomerase detected by in situ hybridization has been demonstrated to be a useful tool for the diagnosis of malignancy and has also been tested by reverse transcriptase-polymerase chain reaction in several tumors such as hepatic cell carcinoma, melanoma, colonic carcinoma, gastric carcinoma, biliary carcinoma, breast carcinoma, mesothelioma, lung carcinoma, female tract carcinoma, and prostatic carcinoma.
  • Fifty-five specimens of diverse prostatic lesions were selected for study (43 needle biopsies and 12 transurethral resections); there were 61 malignancies (47 infiltrating carcinomas and 14 high-grade prostatic intraepithelial neoplasias [PIN]) and 29 benign lesions (10 basal cell hyperplasias, 12 nodular hyperplasias, 4 chronic prostatitis, and 3 atrophic glands).
  • Signal for hTERT nucleolar was detected in 31 of 47 infiltrating adenocarcinomas, in 11 of 14 PIN, and in none of 27 benign lesions (sensitivity, 71%; specificity, 100%).
  • Diffuse cytoplasmic positivity for AMACR was found in 37 of 41 infiltrating adenocarcinomas, in 7 of 7 PIN, and in 6 of 22 benign lesions (sensitivity, 91%; specificity, 72%).
  • [MeSH-major] Adenocarcinoma / enzymology. DNA-Binding Proteins / metabolism. Immunoenzyme Techniques / methods. Prostatic Intraepithelial Neoplasia / enzymology. Prostatic Neoplasms / enzymology. Racemases and Epimerases / metabolism. Telomerase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844561.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; EC 2.7.7.49 / Telomerase; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


91. Houghton O, McCluggage WG: The expression and diagnostic utility of p63 in the female genital tract. Adv Anat Pathol; 2009 Sep;16(5):316-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • p63 plays a key role in epithelial development in various organs, being expressed in myoepithelial cells and in basal cells of stratified epithelia.
  • In the female genital tract, p63 is expressed in the basal and parabasal cells of mature cervical, vaginal and vulval squamous epithelium, and also in cervical reserve cells at the transformation zone and in immature metaplastic and atrophic cervical squamous epithelium.
  • One of the most useful applications of p63 is in the evaluation of problematic cervical carcinomas; most squamous carcinomas exhibit diffuse nuclear immunoreactivity whereas most adenocarcinomas and neuroendocrine carcinomas are negative or focally positive.
  • In conjunction with neuroendocrine markers, p63 is useful in distinguishing between a squamous carcinoma and a small cell or large cell neuroendocrine carcinoma.
  • In the normal endometrium, a population of p63-positive cells is present which may act as a stem cell population and which is increased in various forms of metaplasia.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma / metabolism. Cervical Intraepithelial Neoplasia / diagnosis. Genital Neoplasms, Female / diagnosis. Hyperplasia / metabolism. Membrane Proteins / metabolism. Trophoblastic Tumor, Placental Site / metabolism
  • [MeSH-minor] Cell Nucleus / metabolism. Diagnosis, Differential. Female. Genitalia, Female / metabolism. Humans. Metaplasia / diagnosis. Metaplasia / metabolism. Pregnancy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19700941.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins
  • [Number-of-references] 31
  •  go-up   go-down


92. Ueo T, Kashima K, Daa T, Kondo Y, Sasaki A, Yokoyama S: Immunohistochemical analysis of morules in colonic neoplasms: morules are morphologically and qualitatively different from squamous metaplasia. Pathobiology; 2005;72(5):269-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ten cases of morule-associated colonic neoplasms (4 adenocarcinomas, 1 adenoma with carcinoma in situ, and 5 adenomas), and 3 cases of squamous metaplasia in colonic adenocarcinoma were examined morphologically and immunohistochemically.
  • Furthermore, p63 and 34betaE12 positivities in morules suggested that they have a basal/stem cell phenotype.
  • We consider that morules in colonic neoplasms are cell clusters with a basal/stem cell phenotype, and have less proliferative and less invasive potential than other cancer cells.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Carcinoma in Situ / pathology. Colonic Neoplasms / pathology. Immunoenzyme Techniques / methods. Precancerous Conditions / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Cell Nucleus / pathology. Female. Humans. Intranuclear Inclusion Bodies / chemistry. Intranuclear Inclusion Bodies / ultrastructure. Male. Metaplasia / metabolism. Metaplasia / pathology. Middle Aged. beta Catenin / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16374071.001).
  • [ISSN] 1015-2008
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / beta Catenin
  •  go-up   go-down


93. Ramachandran V, Arumugam T, Hwang RF, Greenson JK, Simeone DM, Logsdon CD: Adrenomedullin is expressed in pancreatic cancer and stimulates cell proliferation and invasion in an autocrine manner via the adrenomedullin receptor, ADMR. Cancer Res; 2007 Mar 15;67(6):2666-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenomedullin is expressed in pancreatic cancer and stimulates cell proliferation and invasion in an autocrine manner via the adrenomedullin receptor, ADMR.
  • The current study investigated adrenomedullin as a potential autocrine regulator of pancreatic cancer cell function.
  • Adrenomedullin was localized in the neoplastic epithelium of 90% (43 of 48) of human pancreatic adenocarcinomas analyzed by immunohistochemistry and was expressed by 100% (8 of 8) of pancreatic cancer cell lines analyzed by reverse transcription-PCR.
  • Pancreatic cancer cell lines also secreted adrenomedullin into the culture medium as determined by ELISA (5 of 5).
  • Exogenous adrenomedullin treatment of Panc-1, BxPC3, and MPanc96 cells in vitro stimulated cell proliferation, invasion, and nuclear factor kappaB activity, indicating the ability of the cells to respond to adrenomedullin.
  • Treatment of the cell cultures with an adrenomedullin antagonist inhibited basal levels of proliferation and nuclear factor kappaB activity, supporting the autocrine function of this molecule.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adrenomedullin / physiology. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Receptors, Peptide / metabolism
  • [MeSH-minor] Animals. Cell Growth Processes / drug effects. Cell Growth Processes / physiology. Cell Line, Tumor. Humans. Male. Mice. Mice, SCID. NF-kappa B / metabolism. Neoplasm Invasiveness. RNA, Small Interfering / genetics. Receptors, Adrenomedullin


94. Attlmayr B, Garrido C, Alderson DJ: Difficulty in establishing a diagnosis in an uncommon presentation of a minor salivary gland tumour. BMJ Case Rep; 2010;2010
MedlinePlus Health Information. consumer health - Swallowing Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Difficulty in establishing a diagnosis in an uncommon presentation of a minor salivary gland tumour.
  • A firm diagnosis of malignancy could not be made histologically.
  • The differential diagnosis included polymorphous low-grade adenocarcinoma, basal cell adenoma and adenoid cystic carcinoma.
  • However, on balance, based on the clinical presentation, a diagnosis of malignancy was favoured and appropriate treatment was considered.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / pathology. Airway Obstruction / etiology. Deglutition Disorders / etiology. Salivary Gland Neoplasms / diagnosis. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor. Tongue Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy. Cooperative Behavior. Diagnosis, Differential. Endoscopy. Humans. Interdisciplinary Communication. Lymphatic Metastasis / pathology. Lymphatic Metastasis / radiotherapy. Magnetic Resonance Imaging. Male. Middle Aged. Palliative Care. Tongue / pathology. Tracheostomy

  • MedlinePlus Health Information. consumer health - Choking.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Dis. 2002 Sep;8(5):229-40 [12363107.001]
  • [Cites] Am J Surg. 1991 Oct;162(4):330-6 [1659242.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jun 1;35(3):443-54 [8655366.001]
  • [Cites] Cancer Treat Rev. 1996 Nov;22(6):395-423 [9134002.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Apr;87(4):485-92 [10225632.001]
  • [Cites] Ann Surg. 1956 Sep;144(3):366-83 [13363274.001]
  • [Cites] Oral Oncol. 2008 Apr;44(4):407-17 [17825603.001]
  • (PMID = 22798299.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC3029651
  •  go-up   go-down


95. Vesely DL: Metabolic targets of cardiac hormones' therapeutic anti-cancer effects. Curr Pharm Des; 2010;16(9):1159-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Within the ANP prohormones are 4 peptide hormones, i.e. atrial natriuretic peptide, vessel dilator, kaliuretic peptide and long-acting natriuretic peptide (LANP) which decrease up to 97% of human pancreatic, breast, colon, prostate, kidney and ovarian carcinomas as well as small-cell and squamous cell lung cancer cells within 24 hours in cell culture.
  • In vivo these 4 cardiac hormones eliminate up to 80% of human pancreatic adenocarcinomas, 2/3rds of human breast cancers, and up to 86% of human small-cell lung cancers in athymic mice.
  • These 4 cardiac hormones inhibit up to 95% of the basal activity of Ras, 98% of the phosphorylation of MEK 1/2 and 97% of the activation of basal activity of ERK 1/2.
  • [MeSH-minor] Animals. Cell Nucleus / metabolism. Drug Screening Assays, Antitumor. Humans. Models, Biological. Receptors, Atrial Natriuretic Factor / agonists

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20030620.001).
  • [ISSN] 1873-4286
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 85637-73-6 / Atrial Natriuretic Factor; 9007-49-2 / DNA; EC 4.6.1.2 / Receptors, Atrial Natriuretic Factor
  • [Number-of-references] 89
  •  go-up   go-down


96. Epstein JI: Prostatic ductal adenocarcinoma: a mini review. Med Princ Pract; 2010;19(1):82-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostatic ductal adenocarcinoma: a mini review.
  • Prostatic ductal adenocarcinomas may arise either in large primary periurethral prostatic ducts or in the peripheral prostatic ducts.
  • Ductal adenocarcinomas are composed of tall columnar cells arranged in cribriform, papillary, solid, single glands, and PIN-like patterns.
  • Other than the prostatic intraepithelial neoplasia (PIN)-like ductal pattern, which behaves like Gleason pattern 3, ductal adenocarcinoma is comparable to Gleason pattern 4 prostate cancer.
  • Ductal adenocarcinoma can have a patchy basal cell layer and typically expresses prostate-specific antigen (PSA) immunohistochemically.
  • Mimickers of ductal adenocarcinoma include prostatic urethral polyps, hyperplastic benign prostate glands, high-grade PIN, colorectal adenocarcinoma, and papillary urothelial carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Ductal / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19996627.001).
  • [ISSN] 1423-0151
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 19
  •  go-up   go-down


97. Wang Y, Zhou ZG, Xia QJ, Zhang WY, Li HG, Wang R: [Expression of minichromosome maintenance protein 2 in colonic adenocarcinoma, adenoma and normal colonic mucosa and its clinical significance]. Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Sep;11(5):465-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of minichromosome maintenance protein 2 in colonic adenocarcinoma, adenoma and normal colonic mucosa and its clinical significance].
  • OBJECTIVE: To investigate the expression differences of minichromosome maintenance 2 (MCM2) mRNA and protein among colon adenocarcinoma, colon adenoma and normal mucosa, and among different clinicopathological types of adenomas.
  • METHODS: Fifty specimens, including 33 colonic adenomas, 12 colonic adenocarcinomas and 5 normal colonic mucosa were selected.
  • Expression differences of MCM2 mRNA among the colonic adenocarcinoma, adenoma and normal colonic mucosa were evaluated by REST-XL software.
  • RESULTS: The expression of MCM2 was observed in the basal third to half of the colonic crypts in normal mucosa, while throughout the epithelium in the colonic adenocarcinomas and adenomas.
  • However, the expression of MCM2 mRNA in the adenocarcinomas was significantly higher than that in the adenomas(P=0.001).
  • CONCLUSION: The difference of MCM2 expression between the adenoma and the adenocarcinoma indicates its potential value in the early diagnosis of colonic cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Cell Cycle Proteins / metabolism. Colonic Neoplasms / metabolism. Nuclear Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18803052.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


98. Peterson MR, Piao Z, Bazhenova LA, Weidner N, Yi ES: Terminal respiratory unit type lung adenocarcinoma is associated with distinctive EGFR immunoreactivity and EGFR mutations. Appl Immunohistochem Mol Morphol; 2007 Sep;15(3):242-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Terminal respiratory unit type lung adenocarcinoma is associated with distinctive EGFR immunoreactivity and EGFR mutations.
  • Approximately 10% to 20% of nonsmall cell lung cancer patients respond to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as gefitinib.
  • A recent study reported that the terminal respiratory unit (TRU)-type adenocarcinoma shares the clinical profile and EGFR mutations of gefitinib responders.
  • EGFR positivity was seen most frequently in squamous cell carcinomas (77%), followed by TRU-type adenocarcinomas (63%), large cell carcinomas (23%), and non-TRU-type adenocarcinomas (12%).
  • A distinctive basally oriented cytoplasmic positivity was observed exclusively in TRU-type adenocarcinomas.
  • EGFR mutation was identified in 6 of 54 cases studied and all 6 cases were TRU-type adenocarcinomas.
  • Five of six cases with EGFR mutation were positive for EGFR immunostain with the basal cytoplasmic localization.
  • In conclusion, EGFR immunoreactivity with basal cytoplasmic pattern was exclusively seen in TRU-type adenocarcinoma and a subset of these cases was seen with EGFR mutations in the responders to EGFR inhibitor therapy.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721266.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


99. Thiel A, Ganesan A, Mrena J, Junnila S, Nykänen A, Hemmes A, Tai HH, Monni O, Kokkola A, Haglund C, Petrova TV, Ristimäki A: 15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer. Clin Cancer Res; 2009 Jul 15;15(14):4572-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: Clinical gastric adenocarcinoma samples were analyzed by immunohistochemistry and quantitative real-time PCR for protein and mRNA expression of 15-PGDH and for methylation status of 15-PGDH promoter.
  • The effects of interleukin-1beta (IL-1beta) and epigenetic mechanisms on 15-PGDH regulation were assessed in gastric cancer cell lines.
  • RESULTS: In a gastric cancer cell line with a very low 15-PGDH expression (TMK-1), the 15-PGDH promoter was methylated and treatment with a demethylating agent 5-aza-2'-deoxycytidine restored 15-PGDH expression.
  • In a cell line with a relatively high basal level of 15-PGDH (MKN-28), IL-1beta repressed expression of 15-PGDH mRNA and protein.
  • SiRNA-mediated knockdown of 15-PGDH resulted in strong increase of prostaglandin E(2) production in MKN-28 cells and increased cell growth of these cells by 31% in anchorage-independent conditions.
  • In clinical gastric adenocarcinoma specimens, 15-PGDH mRNA levels were 5-fold lower in gastric cancer samples when compared with paired nonneoplastic tissues (n = 26) and 15-PGDH protein was lost in 65% of gastric adenocarcinomas (n = 210).
  • [MeSH-minor] Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Cell Line, Tumor. Cell Proliferation. CpG Islands / genetics. Cyclooxygenase 2 / genetics. Cyclooxygenase 2 / metabolism. Cyclooxygenase Inhibitors / pharmacology. DNA Methylation / drug effects. Dinoprostone / metabolism. Gene Expression Regulation, Enzymologic / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Humans. Immunohistochemistry. Interleukin-1beta / pharmacology. Nitrobenzenes / pharmacology. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / genetics. Reverse Transcriptase Polymerase Chain Reaction. Sulfonamides / pharmacology. Transfection

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19584167.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Interleukin-1beta; 0 / Nitrobenzenes; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Sulfonamides; 123653-11-2 / N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; 776B62CQ27 / decitabine; EC 1.1.1.- / Hydroxyprostaglandin Dehydrogenases; EC 1.1.1.141 / 15-hydroxyprostaglandin dehydrogenase; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; K7Q1JQR04M / Dinoprostone; M801H13NRU / Azacitidine
  •  go-up   go-down


100. Leung EL, Tam IY, Tin VP, Chua DT, Sihoe AD, Cheng LC, Ho JC, Chung LP, Wong MP: SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy. Mol Cancer Res; 2009 Jun;7(6):923-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Molecular-targeted therapy using tyrosine kinase inhibitors against epidermal growth factor receptor (EGFR) is an effective therapy for non-small cell lung cancer that harbor EGFR mutations.
  • The results showed that SKI-1 induced significant apoptosis in a dose-dependent manner in cancer cells with high basal Src activation.
  • In 152 adenocarcinomas studied, p-Src was associated with EGFR mutations (P = 0.029).
  • Overall, the findings indicated that Src could be a useful target for treatment of non-small cell lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / enzymology. Lung Neoplasms / enzymology. Receptor, Epidermal Growth Factor / genetics. src-Family Kinases / metabolism
  • [MeSH-minor] Apoptosis / drug effects. Cell Line, Tumor. Cell Movement / drug effects. Gene Amplification. Humans. Immunohistochemistry. Mutation. Neoplasm Invasiveness. Phosphorylation / drug effects. Protein Kinase Inhibitors / pharmacology. Quinazolines / pharmacology. RNA, Small Interfering / genetics. RNA, Small Interfering / metabolism. Reproducibility of Results






Advertisement